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ABSTRACT 
 
Chronic diseases such as type 2 diabetes and the Metabolic Syndrome create enormous 
burdens on society. Epidemiological studies now strongly implicate intrauterine growth 
restriction (IUGR) for increasing the risk of developing chronic diseases later on in life. 
However, the molecular mechanisms underlying how IUGR leads to the increased 
susceptibility to these metabolic diseases in adulthood is not well understood. The Liver-
X-Receptor (LXR) is a nuclear receptor involved in cholesterol, glucose, and lipid 
metabolism. LXR acts to decrease gluconeogenesis through repression of glucose-6-
phosphatase(G6Pase), phosphoenolpyruvate carboxykinase(PEPCK), and 11β-
hydroxysteroid dehydrogenase type-1(11β-HSD1). Using a well-characterized model of 
maternal protein restriction in rats, this study attempts to elucidate the role of LXR in the 
long-term programming of impaired glucose homeostasis. It was discovered that altered 
expression of LXR during the gestational and neonatal period predisposes the fetus to 
impaired glucose tolerance in adult life through LXR-mediated activation of the 
gluconeogenic genes G6Pase, PEPCK, and 11β-HSD1. 
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Chapter One: Introduction - Literature Review 
 
 
 
 
 
 
Excerpts of this chapter have been previously published: T. Vo & D.B. Hardy. Molecular 
mechanisms underlying the fetal programming of adult disease. Journal of Cell 
Communication and Signaling. (6)3: 139-53, 2012. 
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Introduction and Literature Review 
1.1 Chronic Diseases and the Metabolic Syndrome 
Chronic, non-communicable diseases create a vast burden on society, both 
socially and economically. Non-communicable diseases rather than infectious diseases 
are now the leading causes of death worldwide. For instance, in the United States, 
cardiovascular disease is the number one cause of death, responsible for almost 30% of 
all deaths in the country1,2. Other chronic illnesses include hypertension, hyperlipidemia, 
impaired glucose tolerance, and obesity, which, in combination, encompass the metabolic 
syndrome3. The metabolic syndrome is defined by the following criteria: abdominal 
obesity, dyslipidemia, hypertension, insulin resistance and/or glucose intolerance, a 
proinflammatory state, and a prothrombotic state4. More specifically, the metabolic 
syndrome is characterized by the following parameters: abdominal circumference ≥102 
cm in men and ≥88cm in women; triglycerides ≥ 1.7mM in men and women; fasting 
glucose ≥ 5.6mM in men and women; HDL cholesterol ≤ 1.1mM in men and ≤ 1.3mM in 
women; and blood pressure ≥130/85mmHg in men and women5. Along with obesity, the 
metabolic syndrome greatly increases the risk of developing further diseases such as type 
2 diabetes and cardiovascular disease6. To put a number on these figures, more than one 
in three Americans is obese7, while in Canada, more than one in four Canadians is obese8. 
The extensive development of these chronic diseases is not only a problem in North 
America, but worldwide as well2,9-12. The increasing prevalence of the metabolic 
syndrome and obesity is becoming apparent even in the developing world, where under 
nutrition used to be of great concern13-15. Undoubtedly, the growing incidence of these 
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chronic diseases is a worldwide phenomenon that needs to be addressed. Yet, the burden 
of these diseases is extremely complex in nature and the solutions are no less complex.  
Although the prevalence of these chronic and non-communicable diseases puts 
tremendous strain on the health care system and society, intervention with diet or drugs 
can play a significant role to reduce their incidence. For example, a meta-analysis 
prospective study, using data from 58 clinical trials as well as nine cohort studies, 
indicates that in patients with vascular disease, a 1.8 mM reduction in LDL cholesterol by 
statins resulted in a 17 % reduction in stroke and a 60% reduction in the risk of ischemic 
heart disease16. Current treatment of type 2 diabetes and the metabolic syndrome include 
improvements in lifestyle through healthy dieting and increasing exercise, along with the 
use of pharmaceuticals (e.g. metformin or glucagon-like peptide-1 (GLP-1) analogues). 
Unfortunately, these treatments are not efficacious for all individuals. For example, in 
some patients statin treatment can lead to rhabdomyolysis and hepatitis-associated liver 
failure16. As well, some patients of non-communicable diseases, such as type 2 diabetes, 
may become dependent on pharmaceuticals for their entire life and have to live with 
common side effects of the drugs (e.g. gastrointestinal discomfort, heartburn, and 
nausea), which can lead to a decreased quality of life17. Recent studies on the treatment of 
type 2 diabetes indicate that while there were improvements in risk factor control and 
lifestyle, nearly half of diabetic individuals did not reach their goals for control of their 
disease18. Thus, research is now focusing on strategies for disease prevention, in addition 
to the current interventions, to decrease the devastating burden of the non-communicable 
disease pandemic. 
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1.2 Low Birth Weight and Intrauterine Growth Restriction 
The prevalence of low birth weight babies (defined as ≤2500 g or 5.5lbs) 
worldwide is estimated to be 15.5 %, and that number is greatly underestimated19. As a 
general indicator of public health, it is imperative that we study the etiology and 
outcomes of the individuals that develop as low birth weight babies. Low birth weight 
babies are often referred to as being “small for gestational age” (SGA) and are 
traditionally defined as being born with a birth weight ≤ 10th percentile20. Evidence 
strongly suggests that SGA infants are susceptible to higher rates of mortality and 
morbidity21-23. Several definitions have arisen to classify whether an infant should be 
constituted as SGA or not. The classic definition of an SGA infant was that its weight 
was in the lowest 10th percentile for gestational age20. However, this definition does not 
take into account constitutional factors such as ethnicity, infant sex, or parity. Thus, 
optimized and specific growth curves generated for infants and fetuses of different sex, 
ethnicity, and other factors have been adopted to better classify SGA infants24-26.  
SGA infants are often a result of intrauterine growth restriction (IUGR). IUGR 
infants are defined as infants who do not fully reach their growth potential due to genetic 
and/or environmental factors27. It is postulated that approximately one third of these 
IUGR infants arise due to genetic factors, while two thirds are a result of environmental 
influence27. IUGR can also be classified into two categories, symmetric and asymmetric. 
Symmetric IUGR occurs when the entire fetus’ growth is stunted in a proportional 
manner. Asymmetric IUGR occurs when the fetus’ growth is stunted in a disproportional 
manner, such that vital organs (e.g. the brain and heart) receive the most nutrients and 
energy at the expense of other organs (e.g. liver). The redistribution of blood flow from 
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the peripheral organs to the brain is also known as the “brain sparing effect”28. The 
asymmetric growth stunted fetus usually displays a normal head circumference with a 
reduced abdominal circumference. These fetuses usually arise from cases of placental 
insufficiency IUGR29 and are at a higher risk of developing neonatal complications (e.g. 
respiratory distress, sepsis, and intraventricular hemorrhage) than their symmetric IUGR 
counterparts30. 
IUGR can arise from a variety of factors including, infection31,32, chronic 
maternal hypoxia33-35, maternal malnutrition36,37, maternal body composition and 
gestational weight gain/loss38,39, glucocorticoid exposure40, and placental dysfunction41 
(Figure 1.1). Interestingly, the spacing of pregnancies may also influence the 
development and growth of fetuses42,43, with decreased spacing between pregnancies 
correlating to subsequent lower birth weights. It should be noted that while any single 
one of these factors may influence fetal growth and development, these factors might also 
be compounded to impair fetal growth and development even further.  
 
1.3 Developmental Origins of Health and Disease 
The developmental origins of health and disease first stemmed from the “Barker 
Hypothesis” (or “Thrifty Phenotype Hypothesis”). The Barker Hypothesis suggests that 
impaired growth of the fetus during gestation strongly correlates to the development of 
chronic disease in later life44,45. One of the first pieces of evidence linking fetal life and 
chronic disease was a study done by Barker and Osmond (1986) where a strong positive 
correlation was found between the prevalence of ischemic heart disease and the 
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prevalence of neonatal and post neonatal mortality in populations throughout England 
and Wales46. Subsequent studies by Barker and colleagues found evidence that infants 
with the lowest birth weights possessed the highest blood pressures in adulthood and 
were the most likely to die from ischemic heart disease47,48.  Further evidence also 
emerged that demonstrated links between low birth weight and impaired glucose 
tolerance at age 5049 and an even stronger connection was found between low birth 
weight babies and the development of the metabolic syndrome50. Additional 
epidemiological studies have also demonstrated strong correlation between low birth 
weight infants and the development of impaired glucose tolerance and type 2 diabetes, 
cardiovascular disease, and hypertension51-57. Altogether, these studies provide 
considerable evidence that a relationship exists between prenatal growth and 
development and the development of chronic disease in later life. 
It is postulated by the Barker Hypothesis that the fetus is physiologically 
“programmed” in utero to adapt to its environment58-60. In cases of maternal nutritional 
deficiency or placental insufficiency, the fetus must program itself for a poor nutritional 
postnatal environment.  However, this adaptation becomes maladaptive when the infant is 
exposed to a dissimilar postnatal environment. An example is an environment of 
nutritional surplus. Evidence of this is supported by two studies of two different 
populations during World War II. First, a study examining the glucose tolerance of 
individuals born during the Dutch hunger winter (in World War II) found that these 
individuals had lower birth weights and impaired glucose tolerance compared to those 
born a year before or after the famine52. However, another study that examined the 
glucose tolerance of individuals from the Leningrad siege famine (also in World War II) 
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found no differences in glucose tolerance between infants born during the famine and the 
infants born outside of the siege (unexposed to the famine)61. A major difference between 
these two populations was that the Dutch hunger winter siege had lasted less than 6 
months, while the Leningrad siege had lasted 28 months. Thus, infants from the Dutch 
hunger winter siege would have received a higher nutrient intake earlier than those 
infants from the Leningrad siege, who would have continued on a low nutrient diet for 
longer postnatally62. It is believed that the Dutch hunger winter infants experienced a 
mismatch in environment and “catch-up” growth, leading to the programmed glucose 
intolerance in adulthood, while the Leningrad infants did not experience the mismatch in 
environment until much later62. Thus, it is a mismatch in the prenatal and postnatal 
environment and the accompanying maladaptation during a critical time point that is 
strongly related to the development of chronic disease in later life.  
Lastly, the concept of accelerated “catch-up” growth also appears to play a factor 
in the development of chronic disease and reduced lifespan63. Catch-up growth generally 
occurs when the development of a growth restricted organism is accelerated to 
compensate for its impaired growth in early life. While this compensation helps the 
organism grow in its early stages, this growth trajectory appears to exacerbate the 
programming of disease and decreased longevity in later life63. For instance an early 
study done by Crowther et al. (1998) found that low birth weight in addition to rapid 
childhood weight gain was closely associated with the development of impaired glucose 
tolerance64. Similarly, a study by Forsén and colleagues (1999) found that individuals at 
greatest risk for coronary heart disease were those who were born with low birth weights 
and experienced accelerated catch-up growth65. A subsequent study by Eriksson et al. 
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(2001) found similar results in males only66, while Fewtrell et al. (2000) found that 
increased plasma insulin concentrations were associated with accelerated growth patterns 
during childhood67. Additionally, the development of childhood obesity is also strongly 
related to accelerated weight gain during the first 4 months of childhood, regardless of 
birth weight68. Finally, a study in which preterm infants (usually born low birth weight) 
were given a fortified formula diet after birth (accelerated growth) displayed higher 
markers of insulin resistance during adolescence than those given a lower nutrition 
donated breast milk diet69. Taken together, these human studies provide strong evidence 
for the role of accelerated postnatal growth in contributing to the development of adult 
chronic diseases, especially in cases of prenatal growth restriction.  
Thus, it appears that there are two critical periods for the programming and 
development of chronic diseases in adulthood – the prenatal period and the neonatal 
period. The first few weeks of life appear to be especially sensitive to the effects of 
nutrition and catch-up growth69. This makes sense because the neonatal period is a period 
of tremendous growth and development70,71. Yet, the mechanisms behind how insults that 
occur during these critical time periods lead to the programming of adult disease are still 
under investigation. Consequently, many animal models of intrauterine growth restriction 
and fetal programming have been developed to study the physiology and 
pathophysiology of the developmental origins of health and disease.  
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1.4 Animal Models of IUGR 
A variety of animal models have been developed to study the developmental 
origins of adult diseases and fetal programming. Experiments of IUGR in animal models 
provide further evidence to support the hypothesis that impaired growth in utero via 
various maternal deficiencies leads to impairment of glucose, cholesterol, and triglyceride 
metabolism in adulthood72-75. In addition, these animal models provide avenues to 
elucidate the mechanisms behind the fetal programming of adult diseases. In utero 
deficiencies that can lead to impaired growth in humans and animals include hypoxia76, 
deficiencies in essential vitamins and minerals77, diminished protein75, total caloric 
restriction78, excess glucocorticoids79,80, and placental dysfunction41 (Figure 1.1). 
Although the correlation between impaired fetal growth and the risk for developing 
chronic disease in adulthood is undoubtedly strong, the mechanisms behind these 
programming effects are only beginning to be elucidated. A few proposed mechanisms 
underlying the fetal programming of adult disease include altered epigenetic and 
transcriptional regulation, altered nuclear receptor activities, increased oxidative stress, 
and increased endoplasmic reticulum stress resulting in protein misfolding81. Studies 
have only begun to scratch the surface in understanding the molecular events responsible 
for the altered physiology and pathophysiology of these chronic diseases. 
 
1.4.1 Maternal Protein Restriction 
 Maternal protein restriction (MPR) in animals, and especially rodents, is a well-
established model of IUGR that is used to study the developmental origins of health and 
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disease. Due to the fact that placental insufficiency during pregnancy leads to protein and 
amino acid deficiencies in the developing fetus82, the MPR model of IUGR shares many 
similarities with placental insufficiency-related IUGR83. In general, the model employs a 
protein-restricted diet (5-8% protein content) to mothers during the gestation and the 
weaning periods, which is up to three weeks after birth in rats. After the weaning period 
(or in some cases, after birth), the offspring are given a diet restored in protein (generally 
15-20% protein content). Studies from our own laboratory have found that MPR 
offspring exhibit a 15% lower fetal to placenta weight ratio and a 40% decreased fetal 
liver to body weight ratio at embryonic day 1975. Notably, the MPR model does not alter 
the sex ratio of the offspring, litter size, or food intake in the offspring75,84. 
The first few studies of maternal protein restriction in rats found that the offspring 
were born low birth weight and displayed impaired pancreas development85. Further 
studies by the same group and others found impaired pancreas function and development 
and impaired glucose tolerance in later life72,84. Petrik et al. (1999) in particular found 
changes in β-cell replication, increased β-cell apoptosis, and decreased insulin growth 
factor-2 (IGF-2) expression in the pancreas. Hales and colleagues (1996) also found 
impaired glucose tolerance in MPR offspring (at a much later age) as well as predicting 
two different mechanisms for differences seen between the glucose intolerance in males 
versus females86. They postulate that males develop insulin resistance, while females 
develop glucose intolerance due to a lack of insulin. More recent studies by Chamson-
Reig and colleagues (2009) have also found impaired glucose tolerance in MPR offspring 
occurring in a sexually dimorphic manner87.  
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In addition to the pancreas, Burns and colleagues (1997) demonstrated impaired 
liver development and function in addition to hepatic structural changes in the offspring 
of MPR rats88. Another study found increased hepatic glycogen storage in young MPR 
rats89. Furthermore, studies from our lab recently demonstrated that MPR leads to 
epigenetic-mediated repression at the Cyp7a1 promoter, an essential enzyme responsible 
for cholesterol conversion into bile acids, ultimately resulting in elevated cholesterol in 
adulthood75. Other organs that appear to be affected by MPR long-term include the 
heart90,91 and kidneys92,93. 
The MPR model in rodents can also be used to examine the effect of IUGR and 
catch-up growth. It has been previously demonstrated in our laboratory that in a model of 
MPR where protein is restored at an earlier time point (i.e. immediately after birth rather 
than after the weaning period), the offspring exhibit rapid catch-up growth, such that by 
postnatal day 21 the body weight and liver to body weight ratios between the low protein 
offspring and control offspring are unchanged75. This was apparent in both males and 
females and persisted well into early adulthood at postnatal day 130, where the body 
weights and liver to body weight ratios of the catch-up growth animals did not differ 
from the control animals. In contrast, MPR offspring that continued to receive a low 
protein diet after birth until the end of the weaning period, exhibited decreased body 
weights at postnatal day 130, suggesting that they never catch up in body weight75. 
However, in these animals, the liver to body weight ratio at postnatal day 130 was 
unchanged, suggesting that the liver eventually did catch up in growth in the offspring 
restored on a control diet after weaning. This was true for both males and females75.  
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Offspring longevity also appears to be affected in catch-up growth models of 
MPR. In MPR offspring, when protein was restored earlier, the offspring displayed a 
significantly shortened lifespan, suggesting the possibility that accelerated catch-up 
growth may be quite detrimental to growth restricted offspring86,94. One proposed 
mechanism contributing to the decreased lifespan in these accelerated catch-up growth 
offspring is impaired mitochondrial function and increased oxidative stress in the 
kidneys92,93. Other possible mechanisms include altered insulin signaling and sensitivity 
and abrogated reactive oxygen species (ROS) handling in early life95,96. In the reverse 
situation, when the offspring were not protein restricted during gestation and were given 
a low protein diet after birth, they exhibited a longer lifespan86. Ozanne & Hales (2004) 
found similar results in terms of offspring longevity97. Interestingly, they also found that 
the “reverse protein” experimental group (normal protein during gestation and a low 
protein diet during weaning) was protected against the lifespan shortening effects of an 
obesogenic diet97. 
 
 
 
 
 
 
 
 
 Figure 1.1: Factors That May Contribute to Low Birth Weight and The 
Developmental Origins of Health and Disease
several insults) generally leads to intrauterine growth restriction and low birth weight. 
This predisposes the infant to a higher risk of developing chronic disease in adulthood. 
The effect of rapid postnatal catch
effects of programmed chronic disease.
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1.5 The Liver 
The liver is known for its plethora of functions in the body. It is involved in many 
complex processes including detoxification, red blood cell decomposition, glycogen 
storage, bile production, drug metabolism, and energy metabolism. With regards to 
energy metabolism, the liver is mainly responsible for carbohydrate and lipid 
metabolism98. Through coordinated regulation of carbohydrate and lipid metabolism, the 
liver contributes an essential role in the regulation of blood glucose levels. During the 
fasted state the liver maintains a steady supply of glucose to the body via hepatic 
gluconeogenesis. In the post-prandial state, the liver increases hepatic glucose uptake to 
stimulate glycogen production and increase lipogenesis. Perturbations in the regulation of 
hepatic carbohydrate and lipid metabolism leads to the development of many metabolic-
related diseases such as type 2 diabetes99. 
 
1.5.1 Hepatic Gluconeogenesis 
 Two processes determine total hepatic glucose output: glycogenolysis, the 
breakdown of glycogen, and gluconeogenesis, the de novo production of glucose from 
non-carbohydrates (e.g. amino acids, pyruvate, lactate, and glycerol)98. Gluconeogenesis 
is influenced hormonally and by the body’s nutritional state. The rate of gluconeogenesis 
is generally determined by the activities of phosphoenolpyruvate carboxykinase 
(PEPCK), G6Pase (glucose-6-phosphatase), and fructose-1,6-bisphosphatase (FBPase)98. 
For example, in the diabetic and fasted states, the activity of G6Pase is increased100. 
G6Pase is responsible for the enzymatic conversion of glucose-6-phosphate to glucose, 
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the last step of gluconeogenesis. PEPCK is the rate-limiting enzyme that converts 
oxaloacetate into phosphoenolpyruvate, committing oxaloacetate to gluconeogenesis.  
Gluconeogenesis is mainly controlled by the actions of hormones such insulin, 
glucagon, and glucocorticoids. Insulin transcriptionally suppresses the expression of the 
gluconeogenic genes, PEPCK, G6Pase, and FBPase101. In contrast, glucocorticoids and 
glucagon stimulate gluconeogenesis. Insulin signaling appears to be essential in the 
control of hepatic glucose handling, as loss of insulin signaling in the liver leads to severe 
insulin resistance, hyperinsulinemia, impaired glucose intolerance, and an increase in the 
expression of G6Pase, and PEPCK in mice102. Regulation of hepatic gluconeogenesis is 
briefly summarized in Figure 1.2. 
G6Pase is regulated through several pathways. Generally, the insulin-mediated 
suppression of G6Pase involves suppression of the forkhead transcription factor 
(FKHR/FOXO1) by protein kinase B-α (also known as Akt)103. FKHR transcriptionally 
activates G6Pase by binding to one of two insulin response units on the G6Pase 
promoter104. Insulin signaling causes phosphorylation of FKHR, which then leads to the 
expulsion of FKHR from the nucleus and eventual degradation in the cytosol105. 
Phosphoinositide 3-kinase (PI 3-kinase) also appears to be partly involved in insulin-
mediated G6Pase suppression106. G6Pase expression can also be suppressed by the 
mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase 
1/2 (ERK 1/2) –mediated pathway, induced by the phorbol ester PMA107. Furthermore, 
G6Pase expression is downregulated by tumour necrosis factor-α (TNFα) through 
activation of necrosis factor κB (NFκB), although not through direct binding of the 
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G6Pase promoter108. Lastly, G6Pase expression has also been demonstrated to be 
repressed by the liver X receptor (LXR)109,110.  
In contrast, G6Pase expression is induced by glucocorticoids. Administration of 
dexamethasone has been shown to increase G6Pase expression and putative 
glucocorticoid response elements (GRE) have been identified on the G6Pase promoter111. 
Furthermore, the accessory protein hepatic nuclear factor (HNF) appears to be required 
for glucocorticoid-mediated stimulation of G6Pase (and PEPCK)112. Moreover, there are 
cAMP response elements on the G6Pase promoter that are responsive to cAMP 
Responsive Element Binding Protein (CREBP) binding113. 
 PEPCK is transcriptionally regulated in a similar fashion to G6Pase. The main 
suppressor of PEPCK transcription and activation is insulin114. Insulin mediates its 
gluconeogenic suppressive effects through several downstream pathways. One pathway, 
similar to G6Pase regulation, is through the activation of PI 3-kinase113. Furthermore, 
inhibition of FKHR/FOXO1 appears to play a role in the insulin-mediated repression of 
PEPCK, though through a different mechanism than G6Pase115. The transcription factor 
sterol regulatory element binding protein-1 (SREBP-1) also plays a role in the 
suppression of PEPCK expression116. However, SREBP-1-mediated suppression is likely 
to be another intermediate in the insulin-mediated suppression of gluconeogenic genes117. 
Further studies have found that insulin activity stimulates hepatic SREBP-1 expression, 
which then binds to sterol regulatory elements (SRE) on the PEPCK promoter. This 
mechanism represses PEPCK expression by blocking the binding of the stimulatory 
transcription factor SP-1118. Another proposed mechanism for SREBP-1-mediated 
repression of PEPCK is through interference with the peroxisome proliferator-activated 
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receptor coactivator-1 (PGC-1) and hepatic nuclear factor-4 (HNF-4) activation pathway 
of PEPCK119. Like G6Pase, PEPCK is also under transcriptional repression by 
LXR109,110.  
PEPCK is stimulated by glucagon, cyclic-AMP (cAMP) and transcription factors 
such as the glucocorticoid receptor (GR)113. Evidence also suggests that FKHR is 
involved in the transcriptional activation of PEPCK, although through an indirect and 
different pathway than G6Pase115,120. PGC-1 has also been found to be a key co-activator 
in the induction of PEPCK and G6Pase by binding to and co-activating FKHR121. PGC-1 
co-activation of HNF-4 and GR is also required for cAMP- and glucocorticoid- mediated 
activation of PEPCK and G6Pase122. Furthermore, PGC-1 interacts with CREBP to 
activate gluconeogenesis through PEPCK and G6Pase123. 
Aberrant overexpression of the gluconeogenic genes, G6Pase and PEPCK, has 
been found to produce glucose intolerance124,125. Rodent models of diabetes include the 
overexpression of G6Pase126,127. In fact, it is believed that while PEPCK is the rate-
limiting step of gluconeogenesis in the normal state, G6Pase may be the rate-limiting step 
of gluconeogenesis in the diabetic state128. Constant overexpression of G6Pase would 
then lead to chronic increased hepatic glucose output and decreased hepatic glycogen 
storage. It is interesting to note that overexpression of G6Pase does not necessarily lead 
to increases in resting glucose levels but it does lead to elevated glucose levels during 
oral glucose tolerance tests125. Yet, in a mouse model of PEPCK overexpression, basal 
hepatic glucose production was increased but glucose tolerance was not affected during a 
hyperinsulinemic-euglycemic clamp experiment129. Furthermore, these PEPCK-
overexpressing mice demonstrated increased expression of both G6Pase and PEPCK 
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along with insulin resistance specific only to insulin-mediated G6Pase and PEPCK 
signaling (insulin-mediated signaling of GLUT2 and glucokinase were not affected)129. 
These findings highlight the fact that while expression of G6Pase and PEPCK are 
coordinated and tightly regulated through similar pathways, they also demonstrate the 
ability to exert vastly different effects due to the many pathways involved in their 
individual expression. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.2: A Brief Overview of the Regulation of Hepatic Gluconeogenesis.
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1.5.2 Hepatic Lipogenesis 
 The liver plays a critical role in the maintenance of triglyceride levels in the body. 
The overall level of fatty acids and triglycerides in the body is dependent on the balance 
between lipogenesis and lipolysis. The two main sites of lipogenesis are the liver and 
adipose tissue130. Together, these two tissues are responsible for the coordinated 
regulation of fatty acids and triglycerides in the body. In addition, hepatic lipogenesis is 
also tightly associated with the regulation of hepatic carbohydrate metabolism. For 
instance, one of the major functions of hepatic glycolysis is to provide carbon atoms (in 
the form of acetyl-CoA) for de novo lipogenesis98.  
Lipogenesis is highly dependent on nutritional status. For instance, carbohydrate 
intake is a major stimulator of hepatic and adipocyte lipogenesis. An increase in 
carbohydrate intake leads to an insulin spike and insulin is one of the most potent 
stimulators of lipogenesis130. Hyperinsulinemia in rats has been found to increase the 
long-term expression and activity of hepatic lipogenic genes such as fatty acid synthase 
(FAS) and acetyl-CoA carboxylase (ACC)131. Furthermore, it appears that insulin-
mediated lipogenesis requires the induction of the transcription factor sterol regulatory 
element binding protein-1, specifically the 1c isoform (SREBP-1c)132. To further link 
carbohydrate and lipid metabolism, Foretz and colleagues (1999) also found that SREBP-
1c was required for the insulin-mediated activation of glucokinase and lipogenic genes133. 
It is believed that the insulin-mediated induction of SREBP-1 is facilitated through the PI 
3-kinase pathway134.  
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Transcriptional regulation of hepatic lipogenesis is largely mediated by SREBP-
1c, the “master lipid regulator” and an isoform of the SREBP family of proteins135. Many 
of the genes involved in fatty acid synthesis possess SRE or EBOX-motifs on their 
promoters, essential sites for SREBP-1 binding98,134,136. For instance, the promoters of 
FAS and ACC possess binding sites for SREBP-1137,138. Furthermore, mice lacking 
SREBP-1 expression display a severe impairment of lipogenic gene expression135. The 
generation of fatty acids is an essential prerequisite for the generation of triglycerides. 
The rate-limiting step of long-chain fatty acid synthesis is mediated by ACC through 
catalyzing the conversion of acetyl-CoA to malonyl-CoA139. The enzyme FAS is then 
responsible for the repeated addition of malonyl-CoA subunits to acetyl-CoA through 
condensation reactions. After seven cycles, FAS forms its primary product, palmitate (or 
palmitic acid), a saturated 16-carbon fatty acid140. Stearoyl-CoA desaturase-1 (SCD-1) is 
a rate-limiting enzyme for the formation of monounsaturated and polyunsaturated fatty 
acids. It is responsible for adding a cis-orientation double bond to carbons 9 and 10 on a 
variety of acyl-CoAs but prefers palmitoyl- and stearoyl-CoA, which form palmitoleoyl- 
and oleoyl-CoA, respectively141. The resulting monounsaturated fatty acids formed by 
SCD-1 go on to form essential substrates for the production of other unsaturated fatty 
acids, triglycerides, phospholipids, and cholesterol esters141. Rodent studies have strongly 
suggested the overexpression and hyperactivity of these lipogenic genes in the 
development of hypertriglyceridemia and obesity due to their essential role in the 
formation of triglycerides through increased fatty acid production142-145. Hepatic 
lipogenesis is briefly summarized in Figure 1.3. 
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 While carbohydrate intake stimulates the induction of lipogenesis, the presence of 
polyunsaturated fatty acids leads to suppression of lipogenesis. This process appears to be 
mediated through both transcriptional and post-transcriptional mechanisms146-148. 
Lipogenic genes are also suppressed by the presence of polyunsaturated fatty acids 
through decreases in SREBP-1 expression149. Interestingly, the presence of saturated or 
monounsaturated fatty acids do not appear to affect hepatic lipogenesis149. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.3: A Brief Overview of Hepatic Lipogenesis. 
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1.5.3 Hepatic Cholesterol Regulation 
 In addition to its role in glucose and lipid homeostasis, the liver plays a vital role 
in the regulation of cholesterol metabolism and transport. Maintenance of proper 
cholesterol levels is vital to the functioning of an organism. Cholesterol is an essential 
component of the cell membrane and is the precursor to bile acids, steroids, and 
vitamins150. Three processes, de novo cholesterol synthesis, cholesterol catabolism, and 
cholesterol absorption, mediate cholesterol regulation. The two main sources of 
cholesterol in the body come from dietary sources and de novo cholesterol synthesis. 
Although virtually every cell in the body can synthesize cholesterol, the principle site of 
de novo cholesterol synthesis is the liver150. Since cholesterol can be synthesized de novo 
in the body it is not considered an essential nutrient.  
The transcriptional regulation of cholesterol synthesis is principally mediated 
through the actions of the transcription factor SREBP-1151. When the cell detects low 
level of sterols, SREBP-1 is cleaved from the endoplasmic reticulum and translocates to 
the nucleus where it activates transcription of essentially all genes involved in the 
synthesis of cholesterol from acetyl-CoA. These genes include, 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) synthase, HMG-CoA reductase, farnesyl 
pyrophosphate (FPP) synthase, 7-dehydrocholesterol reductase, squalene synthase, and 
lanosterol 14 α-demethylase152,153.  
The regulation of sterol (including cholesterol) absorption in the body is another 
essential point of regulation in cholesterol homeostasis, although much of the process is 
still not very well understood. A majority of the cholesterol ingested into the body is not 
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readily absorbed since it is a relatively inefficient process150. Evidence for the importance 
of cholesterol and sterol absorption regulation comes from studies of sitosterolemia, a 
rare autosomal recessive genetic disorder in which there is a mutation in ATP-binding 
cassette sub-family G member 5 (ABCG5) and/or ABCG8 genes. They encode the 
proteins sterolin-1 and sterolin-2, respectively, and are both expressed exclusively in the 
liver and intestines where they increase the intake and excretion of sterols154. Patients 
with sitosterolemia exhibit elevated circulating cholesterol, and premature 
atherosclerosis. Further evidence for the role of these transporters in sterol regulation 
comes from a study where human ABCG5 and ABCG8 were overexpressed in mice, 
leading to decreased intestinal cholesterol absorption and increased secretion of biliary 
sterols155. Moreover, evidence also suggests that the ATP-binding cassette transporter 
ABCA1 may also play a role in the excretion of dietary cholesterol, in addition to its role 
in “reverse cholesterol transport” (the process of transporting cholesterol from the 
periphery to the liver via the formation of high density lipoproteins)156. These 
transporters, ABCA1, ABCG5, and ABCG8 are principally regulated by a group of 
nuclear receptors known as the liver X receptors157-159. 
Lastly, cholesterol can be eliminated in the body through bile acid synthesis, a 
process that occurs solely in the liver150. Bile acid synthesis occurs through two 
pathways, the classic pathway and the alternate pathway160. Although several enzymes 
exist in the bile acid synthesis pathways (e.g. cholesterol 7α-hydroxylase (Cyp7a1), 25-
hydroxycholesterol 7α-hydroxylase (Cyp7b1), sterol 27-hydroxylase (Cyp27), and sterol 
12α-hydroxylase (Cyp8b)), Cyp7a1 is the most studied and is the rate-limiting enzyme in 
the production of bile acids from cholesterol through the classic pathway161. Cyp7a1 is 
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responsible for the enzymatic conversion of cholesterol to form 7α-hydroxycholesterol. 
Activity of Cyp7a1 is controlled by the ratio of cholesterol to bile acids in the liver and is 
sensitive to the changing concentrations of oxysterols (derivatives of cholesterol) and 
cholesterol162. Increasing oxysterol concentrations mediate increased Cyp7a1 
transcription through LXR, while transcriptional repression is indirectly mediated 
through the bile acid receptor known as the farnesoid X receptor (FXR)162. Other nuclear 
receptors involved in Cyp7a1 transcriptional regulation include the promiscuous nuclear 
receptor known as the retinoid X receptor (RXR), involved in heterodimer formation with 
LXR, the liver receptor homologue-1 (LRH-1), responsible for basal Cyp7a1 induction, 
and the small heterodimer partner (SHP), responsible for antagonizing the actions of 
LRH-1, and ultimately decreasing Cyp7a1 expression162. 
 
1.5.4 Transcriptional Regulation of Hepatic Gene Expression: The Liver X Receptor 
The LXRs (LXRα and LXRβ), part of the 1H subfamily of nuclear receptors, are 
ligand-activated transcription factors. They have long been implicated in the homeostasis 
of cholesterol and fatty acids163,164. Although both LXRs share similar homology (~78%), 
they are expressed in different tissues and are differentially regulated in terms of nuclear 
and cytosolic trafficking150,165. Furthermore, studies have also found that both isoforms 
may be involved in different pathways in the regulation of cholesterol and 
triglycerides166. LXR transcriptionally regulates its downstream target genes by 
heterodimerizing with the retinoid X receptor (RXR) and binding to the LXR Element 
(LXRE) on the promoters of these genes. The LXRE consists of a direct repeat gene 
sequence containing the Direct Repeat-4 (DR-4) motif AGGTCA_4n_AGGTCA, where 
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‘4n’ represents a random nucleotide sequence167. When LXR and RXR are bound to each 
other, they can be activated by ligands for either partner168. LXRα is mainly expressed in 
the liver, adipose tissue, spleen, and lungs168,169, while LXRβ is expressed 
ubiquitously170.  
Known endogenous ligands for LXR include the oxysterols, which are essentially 
derivatives of cholesterol. These oxysterols include 24(S),25-epoxycholesterol and 24(S)-
hydroxycholesterol164. In general, most oxysterols have similar affinities for both LXR 
isoforms with the exception of 6α-hydroxy bile acids, which have a higher affinity for 
LXRα171. In addition to the endogenous oxysterol ligands for LXR, the non-steroidal 
agonists GW3965 and T0901317 are potent activators of LXR172,173. Natural antagonists 
for LXR include constituents of mevalonate metabolism (e.g. geranylgeraniol and 
geranylgeranyl pyrophosphate), 5α,6α-epoxycholesterol-3-sulfate (ECHS), and 7-
ketocholesterol-3-sulfate174-176. Studies have shown that LXR also possesses the ability to 
autoregulate itself177-179. These studies have demonstrated that there are LXREs present 
on the LXR promoter itself and that both endogenous and synthetic ligands for LXR can 
induce transcription of LXR. However, it appears that this mechanism of autoregulation 
is found largely in the human LXR gene, and more specifically in macrophages. 
Interestingly, peroxisome proliferator-activated receptor (PPAR) response elements 
(PPRE) have also been found on the LXR promoter indicating that ligands for PPAR (e.g. 
PPARγ) can also induce the transcription of LXR177,180.  
 Owing to its activation by oxysterols and its presence in the liver and 
macrophages, LXR has principally been implicated in regulating genes involved in the 
metabolism and transport of cholesterol157,164,181 (Figure 1.2). LXR was first found to 
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enhance expression of cholesterol 7α-hydroxylase, also known as Cyp7a1164. Cyp7a1 is 
responsible for the enzymatic conversion of cholesterol to 7α-hydroxycholesterol, the 
rate-limiting step in the classic conversion of cholesterol to bile acids. In addition to the 
role of LXR in upregulating the conversion of cholesterol to bile acids, it is also involved 
in the transport and excretion of cholesterol158,159. LXR has also been demonstrated to 
increase the transcription of the “half ATP-binding cassette transporters” G5 and G8 
(ABCG5 and ABCG8)158,159, responsible for the excretion of cholesterol and other sterols 
from the liver and intestines. Furthermore, LXR also increases the transcription of ATP-
binding cassette transporter A1 (ABCA1), which is also responsible for cellular 
cholesterol efflux to the protein, apolipoprotein A-1 (Apo-A1), an important step in 
reverse cholesterol transport157,180,182. Overall, the role of LXR in the transcriptional 
regulation of cholesterol metabolism and transport is one of great importance and is 
essential to maintaining adequate levels of cholesterol. Studies have demonstrated that 
LXRα-/- deficient mice display the complete inability to accommodate increased 
cholesterol loads183.  
In addition to its involvement in cholesterol metabolism and transport, LXR has 
also been implicated in the regulation of enzymes involved in fatty acid synthesis (Figure 
1.4). The main target of LXR in the transcriptional regulation of fatty acid metabolism is 
sterol regulatory element binding protein-1c, SREBP-1c184-186. SREBP-1c, also known as 
the “master lipid regulator”, is responsible for transcriptionally inducing many of the 
essential hepatic lipogenic genes (Figure 1.4). These genes include fatty acid synthase 
(FAS), stearoyl-CoA desaturase-1 (SCD-1), and acetyl-CoA carboxylase (ACC) among 
others137,187,188. Out of these genes, SCD-1 appears to be one of the main mediators in 
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LXR-mediated hepatic triglyceride accumulation145. Chu et al. (2006) demonstrated that 
SCD-1 deficient mice were protected against LXR-mediated lipogenic effects and even 
exhibited increased plasma HDL145. However, in addition to being regulated by SREBP-
1c, these genes (FAS, ACC, SCD-1) are also directly regulated by LXR, as they all 
possess functional LXREs in addition to functional SREs145,189,190. This is exemplified in 
mice lacking LXR, which exhibit decreased production of hepatic fatty acids184. Thus, the 
control of hepatic lipogenesis is under coordinated and complementary transcriptional 
regulation between both SREBP-1 and LXR. For instance, LXR has also been 
demonstrated to act as an intermediary for insulin-mediated SREBP-1c activation191. 
Tobin et al. (2002) found that the insulin-mediated regulatory effect on SREBP-1c was 
completely eliminated in LXR deficient mice191. This study was further supported by 
Chen et al. (2004), which demonstrated impaired activation of SREBP-1c when the 
LXREs on the promoter of SREBP-1c were disrupted192. Interestingly, lipogenic effects 
mediated by LXR appear to be primarily mediated by the LXRα isoform166,193. Studies 
done by Lund et al (2006) and Quinet et al (2006), both demonstrated that selective 
pharmacological activation of LXRβ could induce the cholesterol-related effects of LXR 
but not the lipogenic effects.  
Recently, it has been found that LXR may also act as a glucose sensor by binding 
directly to glucose and influencing the expression of genes involved in glucose 
homeostasis194 (Figure 1.4). Mitro et al. (2007) found that in addition to the known 
oxysterols, glucose (D-glucose and D-glucose-6-phosphate) is also very likely to be an 
endogenous ligand for LXR at physiological concentrations comparable to those of the 
oxysterols194. One of the earliest pieces of evidence demonstrating LXR involvement in 
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glucose homeostasis first stemmed from Stulnig et al. (2002), in which a genome-wide 
gene expression analysis was performed in wild-type and LXR knockout mice given an 
LXR agonist109. The study found decreases in the expression of several genes involved in 
hepatic gluconeogenesis including glucose-6-phosphatase (G6Pase), 
phosphoenolpyruvate carboxykinase (PEPCK), and fructose-1,6-biphosphatase (FBPase-
1) in wild-type mice but not LXR deficient mice. Following the Stulnig et al. (2002) 
study, multiple studies were done where pharmacological administration of LXR agonists 
in diabetic phenotype mice led to the stabilization of blood glucose levels and improved 
insulin sensitivity110,195,196. Administration of LXR agonists in non-diabetic mice did not 
appear to affect the blood glucose levels110. However, administration of LXR agonists in 
obese phenotype mice led to stabilization of blood glucose levels and increased insulin 
sensitivity197. These studies proposed LXR-mediated suppression of hepatic 
gluconeogenesis (reduced PEPCK and G6Pase activity) as a possible mechanism for the 
normalization of blood glucose levels in the diabetic mice. It was also suggested that 11β-
hydroxysteroid dehydrogenase 1 (11β-HSD1) and the glucocorticoid receptor (GR) might 
be essential in facilitating the decreased hepatic gluconeogenesis associated with LXR 
activation196. Since LXR has been found to repress 11β-HSD1 expression, a key enzyme 
in the conversion of inactive corticosteroids to active corticosteroids198, the effects of 
decreased glucocorticoid production may also contribute to the observed decrease in 
hepatic gluconeogenesis. As seen with the LXR-mediated lipogenic effects, it appears 
that LXR-mediated effects on glucose metabolism are primarily mediated by the LXRα 
isoform199. On the molecular level, it is still unclear how LXR suppresses hepatic 
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gluconeogenesis, but there is likely interplay between the transcription factors LXR, 
SREBP-1, and GR. 
Finally, LXR has been demonstrated to influence the peripheral uptake of 
glucose, chiefly in peripheral adipose tissue, through the GLUT4 receptor195,197,199. 
Additionally, GLUT1 expression also appears to be induced by increased LXR 
activation200. Studies examining the promoter of GLUT4 and its expression in response to 
LXR agonists have found functional LXREs and direct interactions between LXR and the 
GLUT4 promoter195,201. Interestingly, the role of LXR in adipose tissue seems to contrast 
that of its role in the liver, suggesting that LXR metabolic effects are tissue specific. Ross 
et al. (2002) suggest that in adipose tissue, LXR mediates the uptake of glucose and 
increases lipolysis and glycogen synthesis200. This contrasts the role of LXR in the liver, 
which is to increase hepatic lipogenesis. Furthermore, while GLUT4 is also expressed in 
muscles, it appears that activation of LXR does not influence the regulation of GLUT4 in 
muscle cells195,199. However, there is some disagreement here as Dalen et al. (2003) have 
found that pharmacological activation of LXR does indeed lead to an increase in GLUT4 
mRNA in muscle cells. Conflicting evidence also comes from Kase et al. in 2005, where 
administration of an LXR agonist to human myotubes increased GLUT4 and GLUT1 
mRNA202. 
Due to the role of LXR in increasing peripheral glucose uptake through the GLUT 
receptors and limiting hepatic glucose production through inhibition of the hepatic 
gluconeogenic genes (G6Pase and PEPCK), LXR agonists have been considered as a 
therapeutic agent in the treatment of diabetes110,195. However, due to the lipogenic 
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properties of LXR agonists203, more investigation is required before the therapeutic 
benefits of LXR can be truly considered.  
The role of LXR in regulating glucose, lipid, and cholesterol metabolism is 
summarized in Figure 1.4. 
 
 
 
 
 
 
 
  
 
Figure 1.4: The Role of the Liver X Receptor in Regulating Glucose, Cholesterol 
and Lipid Homeostasis. In general, LXR acts to decrease the level of glucose in the 
blood through two mechanisms. The first is through increasing peripheral glucose upta
in the body (through induction of the GLUT receptors). The second 
through the suppression of glucose production (
G6Pase and PEPCK) and suppression of glucocorticoid production (
11β-HSD1). LXR also decreases cholesterol in the body through the induction of various 
cholesterol metabolism genes: Cyp7a1 (responsible for conversion of cholesterol into bile 
acids) and ABCA1, ABCG5, and ABCG8 (responsible for cholesterol 
LXR is involved in the induction of genes involved in the production of fatty acids and 
ultimately triglycerides. These genes include FAS, ACC, SCD
regulator” SREBP-1. 
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1.6 Transcriptional Regulation of Hepatic Gene Expression: The Role of Epigenetics 
The development of many complex and chronic diseases cannot be simply 
explained with genomic heritability alone204. Epigenetics has emerged as an important 
mechanism in adjusting the expression patterns of genes in a site and tissue specific 
manner as an adaptive response to insults during the developmental period. Epigenetic 
mechanisms essentially influence the long-term expression of a gene by altering the 
ability of the transcriptional machinery to interact with the chromatin environment. 
Moreover, they influence heritable changes in phenotype without altering the genetic 
sequence of an organism. Epigenetic changes can be both transient and persist for long 
periods of time205,206. Mechanisms of epigenetic action include direct DNA methylation, 
post-translational histone modifications, and more recently discovered microRNA- 
mediated repression and activation. 
 
1.6.1 Post-Translational Histone Modifications 
In the eukaryote nucleus, genomic DNA is combined with numerous different 
proteins, including histones, to form chromatin. One purpose of chromatin, among many, 
is to regulate gene expression. The most basic unit of chromatin is the “nucleosome”, a 
length of DNA that is 146 base pairs long and surrounds eight core histones (a pair of 
each of the histones H2A, H2B, H3, and H4)207. Each core nucleosome contains two 
functional domains: a “histone-fold” motif for histone-histone and histone-DNA 
interaction within the nucleosome and a histone tail composed of a terminal –NH2 group 
and –COOH group208. Nucleosomes are linked together by “linker DNA”, which also 
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interacts with histone H1. At the lowest level of organization, genomic DNA surrounds 
the nucleosome to form a structure resembling “beads on a string”. As chromatin 
condenses into higher order structures, it becomes more complex in nature due to the 
countless interactions between the genomic DNA, histones, and a vast array of proteins 
associated with the histones. Furthermore, condensed chromatin is less accessible, more 
stable, and is generally considered transcriptionally inactive. With that being said, even 
today, the precise structure of higher order condensed chromatin is still in question.  
In general, there are two main forms of chromatin. Euchromatin, the least dense 
form of chromatin, is said to be more transcriptionally active as its open structure allows 
easier accessibility for transcriptional machinery and protein interaction. Euchromatin is 
generally associated with increased histone acetylation profiles, a hallmark of chromatin 
opening. The more condensed form of chromatin is known as heterochromatin209,210. 
Unlike euchromatin, heterochromatin is less accessible by transcriptional machinery and 
generally considered transcriptionally inactive. Heterochromatin is generally associated 
with a decreased histone acetylation profile and an increased histone methylation profile, 
which is representative of more stable and inaccessible chromatin. 
A major epigenetic mechanism involves influencing the chromatin environment 
through a number of post-translational modifications on the histone tails (-NH2 domain 
on the histone), including methylation, acetylation, phosphorylation, ubiquitination and 
ADP-ribosylation of histones211,212. Histone tail modifications such as phosphorylation 
and acetylation are more transient, while methylation is considered more stable in 
nature213,214. The combinatorial and unique nature of these covalent modifications reveal 
a “histone code”, which may serve critical as an adaptive regulatory mechanism that can 
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also influence gene expression in a tissue- and gene-specific manner at times of insult 
during development. Furthermore, these histone modifications occur and are maintained 
by a diverse range of histone modifying enzymes including families of histone acetylases 
and methyltransferases215, whose levels may also be altered as a result of a developmental 
insult. It is important to realize that the different prenatal insults that lead to IUGR 
offspring seem to have both common and distinct adaptive responses initiated via 
epigenetic mechanisms. Therefore IUGR offspring derived from different insults may 
differ or be similar due to global, tissue, or site-directed epigenetic modifications. 
 
1.6.2 Histone Acetylation and Increased Gene Activity 
The first evidence of histone acetylation as a mechanism for transcriptional 
activation came from a studies done by Allfrey and colleagues216,217. Later studies went 
on to support the notion that histone acetylation was strongly correlated with active genes 
and increased transcriptional activity218,219. Additional studies then found increased 
interaction between transcription factors and chromatin sites where the histones were 
highly acetylated, further indicating that sites of increased acetylation facilitated 
transcription, likely through increased accessibility for transcriptional machinery (e.g. co-
activators, signaling proteins, and RNA polymerase II)220,221.  
There are several hypotheses that may explain why acetylation of histone tails on 
the nucleosome would lead to increased transcription222. The first hypothesis, as 
mentioned earlier, is based on the belief that acetylation of lysine residues on the histone 
tail leads to the neutralization of the positive charges at these tails and subsequently less 
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interaction between the histone tails and DNA. This decreased interaction would then 
lead to increased accessibility for the transcriptional machinery to bind DNA and 
facilitate increased transcriptional activity. The second hypothesis is that the acetylation 
of lysine residues on the histones (and occasionally non-histones) surrounding the gene in 
a site-specific pattern acts as a signal for corresponding transcriptional machinery. For 
instance, co-activators or co-repressors of a transcription factor may recognize specific 
acetylation patterns for different histones and facilitate or repress transcription. The third 
hypothesis does not involve acetylation of the histone tail itself but acetylation of non-
histone proteins that may associate with the core histones and/or transcriptional 
machinery and facilitate transcription. It should be noted that these hypotheses are not 
mutually exclusive and are very likely acting in concert222. 
The two main families of enzymes responsible for the acetylation and 
deacetylation of histone tails are the histone acetyltransferases (HAT) and histone 
deacetylases (HDAC), respectively (Figure 1.5). The steady-state acetylation profile of 
histones depends on the balance between the activities of HATs and HDACs. 
Interestingly, prior to the discovery of these HATs and HDACs, many of these proteins 
were already known to be functionally involved in transcriptional regulation223. Studies 
found that HATs were generally associated with co-activators, while HDACs were 
associated with generally co-repressors, lending further evidence to the permissive 
actions of histone acetylation and the repressive actions of histone deacetylation223,224. 
HATs, and more specifically, A-type HATs (or HAT-A) are responsible for transferring 
acetyl groups from acetyl-CoA to specific lysine groups on histone tails224. Common sites 
for histone acetylation are lysine residues 9, 14, 18, and 23 on histone H3225,226. HDACs 
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are part of a superfamily and are composed of several different classes, which are 
involved in different cellular processes. HDACs are responsible for the removal of acetyl 
groups from lysine residues on histones (and non-histones), leading to hypoacetylated 
chromatin227. Hypoacetylated chromatin is generally more condensed due to increased 
interaction between the positively charged lysine residues and the negatively charged 
genomic DNA. This decreases the accessibility of transcriptional machinery. To add to 
the already complex nature of histone modifications and transcriptional activation, 
studies have also demonstrated that HDAC activity may also be required for 
transcriptional activation of certain genes228. The opposite has also been found, where 
histone acetylation was required for transcriptional silencing229. Thus, transcriptional 
regulation on the chromatin and histone level requires a delicate balance between 
different acetylation patterns. It should also be noted that some transcription factors 
themselves appear to possess histone acetyltransferase activity222. Finally, though histone 
acetylation is characterized as a highly dynamic and transient histone modification, 
evidence suggests there are also cases where acetylation persists for longer periods of 
time (e.g. mitosis)230. 
 
1.6.3 Histone Methylation and Altered Gene Activity 
 While histone hyperacetylation is strongly linked to increased chromatin 
accessibility and increased transcriptional activity, histone hypermethylation is generally 
associated with decreased transcriptional activity. Unlike the well-studied effects of 
histone acetylation, histone methylation is a relatively new field of study. Chen et al. 
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(1999) did one of the first studies linking histone methylation with transcription, whereby 
they found a strong connection between transcriptional co-activators, methyltransferase 
activity on histone H3, and levels of transcription231. Intriguingly, this first piece of 
evidence linked methylation with increased transcription rather than decreased 
transcription. A further study done by Rea et al. (2000) suggested that methylation of 
histone H3 on lysine 9 was associated with the formation of heterochromatin, 
discouraging the recruitment of transcriptional activators232. Unlike histone acetylation, 
lysine residues can be mono-, di-, and tri- methylated. Furthermore, while enzymes have 
been found to be able to reverse mono- and di- methylation, trimethylation appears to be 
generally irreversible233. This suggests histone trimethylation as a very stable histone 
modification. 
 The main family of enzymes involved in the methylation of histones is the histone 
methyltransferase (HMT) group (Figure 1.5). HMTs catalyze the transfer of methyl 
groups from the methyl donor S-Adenosyl methionine (SAM) to lysine residues or 
arginine residues on histones233. HMTs are commonly known to add methyl groups to 
lysine residues 4, 9, 27, and 36 on histone H3, and lysine residue 20 on histone H4233. 
The specific methylation of lysine residue 9 on histone H3 has been established as a 
recognition site for heterochromatin protein 1 (HP1), a protein involved in 
heterochromatin formation and stabilization as well as gene silencing234,235. HP1 
recognition and recruitment has not been observed for other lysine residues, such as 
lysine 4 on histone H3236. In addition to methylation of lysine 9 on histone H3, 
methylation of histone H3 lysine residue 27 has also been found to be involved in gene 
silencing237, although through a different mechanism. Methylation of lysine 27 on histone 
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H3 was found to facilitate transcriptional repression through recruitment of Polycomb 
group protein complexes237.  
In contrast to methylation of lysine residues 9 and 27, methylation of residue 4 on 
histone H3 has been found to be involved with increased gene transcription238,239. 
Bernstein and colleagues (2002) postulate that methylation of histone H3 lysine 4 
facilitates transcription by protecting the lysine group from deacetylation238. 
Interestingly, Santos-Rosa et al. (2002) found that trimethylation of histone H3 lysine 4 
was purely associated with increased gene transcription, while dimethylation of histone 
H3 lysine 4 was associated with both gene activation and repression239. Furthermore, 
studies have demonstrated that hypermethylation of histone H3 lysine 4 may act as a 
marker or placeholder for genes that were recently transcribed240,241. Given the stable 
nature of histone methylation compared to the other post-translational modifications (e.g. 
acetylation, phosphorylation, ubiquitination), it is the most likely candidate to act as a 
memory marker for transcriptional activity and other vital processes related to the 
genome.  
 Recently, the discovery of histone demethylases has provided much insight into 
the regulation of histone methylation profiles242,243 (Figure 1.5). Prior to the discovery of 
these histone demethylases, it was postulated that methyl groups were removed through 
complete histone replacement and methylation profiles were modified through histone 
turnover233,244. The first lysine specific demethylase to be discovered was lysine-specific 
demethylase 1 (LSD1), which was found to specifically demethylate mono- or di- methyl 
groups from only histone H3 lysine 4242. Further studies identified another group of 
histone demethylases. Histone demethylase JmjC domain-containing histone demethylase 
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1 (JHDM1) was found to be responsible for the demethylation of mono- and di- methyl 
groups on histone H3 lysine 36245, while JHDM2 was found to demethylate mono- and 
di- methyl groups on histone H3 lysine 9246. Further studies uncovered the JMJD2 
subfamily consisting of JMJD2A, JMJD2B, JMJD2C, and JMJD2D247. All members of 
the JMJD2 subfamily have been found to demethylate trimethyl groups on histone H3 
lysine 9248-251. JMJD2A and JMJD2C activity appear to favour the formation of a 
dimethyl group, while JMJD2D activity favours the formation of a single methyl group. 
Taken together, it is highly likely that the delicate balance of gene transcription and 
repression relies on the complex interplay between HATs, HDACs, HMTs, and histone 
deacetylases (Figure 1.5). 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 1.5: Post-Translational Histone Modifications Involved in Chromatin 
Remodeling. Histone demethylases and histone acetyl 
chromatin to “open” it up and provide access for transcriptional machinery. In contrast, 
histone methyl transferases (HMT)
such that it is in a “closed” state, decreasing the likeli
interaction. 
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1.7 Tissue Plasticity: Reversing the in utero Origins of Adult Disease 
The development of many organs occurs both prenatally and postnatally. For 
example, in the liver, development consists of embryonic cell specification, budding, and 
differentiation252. Until birth, the liver has major hematopoietic function253, but by mid-
gestation in rodents, the liver bud is formed containing bipotential progenitor cells that 
differentiate into either hepatocytes or ductal cells254. In the last three days of gestation in 
the rat, liver mass triples due to a high rate of fetal hepatocyte proliferation255, followed 
by a transition of fetal to adult rat hepatocytes in the first week of postnatal life256. Given 
that during this neonatal period there is a high rate of replication, neogenesis and 
apoptosis255 leading to extensive liver remodeling, this period represents a critical 
window for therapy designed to improve hepatic growth and function long-term. For 
example, it has been demonstrated in IUGR rat offspring derived from uterine artery 
ligated dams, that neonatal administration of Exendin-4™, a glucagon-like peptide 1 
(GLP-1) analogue, prevents the development of diabetes due to the restoration of the 
transcription factor pancreatic and duodenal homeobox 1 (Pdx-1), and ultimately cell 
function257. Moreover, Exendin-4™ treatment during this neonatal period also prevented 
the development of hepatic oxidative stress and insulin resistance258. This indicates quite 
remarkably that neonatal intervention in rats can influence both pancreatic and liver 
development long-term, and possibly reverse adverse events encountered during 
gestation. Therefore the goal of future studies is to understand how we can exploit this 
plasticity in organ development to correct the short- and long-term abnormalities 
resulting from an adverse in utero environment. Given that the rat liver develops at a very 
similar timeframe compared to the human liver252, further insights into the reversibility of 
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fetal programming effects on liver development offers promise in human IUGR 
pregnancies.  
Our recent studies indicate that restoration of maternal protein intake during 
lactation can rescue liver growth and prevent the development of hypercholesterolemia 
long-term in the offspring of protein-restricted dams75. However the underlying 
epigenetic and transcriptional mechanisms are unknown. While LXR agonists have been 
demonstrated to activate acetylation of LXR-target promoters and lower LDL cholesterol 
in atherosclerosis-prone adult mice190, their use in neonatal life is limited259. Given 
Cyp7a1 expression is enhanced by histone hyperacetylation260, it is conceivable that LXR 
agonist administration in vivo could boost the expression of LXR target genes, via 
increases in both LXR binding and histone acetylation surrounding the LXRE sites. 
Preliminary evidence from our laboratory suggests that 3-week-old MPR offspring 
treated with an LXR agonist (GW3965) from postnatal day 5 to 15 display decreased 
circulating cholesterol to HDL ratios compared to vehicle treated MPR offspring261. 
These offspring also displayed increased hepatic expression of Cyp7a1, concomitant with 
increased recruitment of RNA polymerase II and acetylation of histone H3 (lysine 9,14) 
surrounding the Cyp7a1 promoter by 3 weeks of age261. Additionally, studies of MPR in 
embryonic day 19.5 mice have demonstrated that LXR expression is decreased in MPR 
offspring during the neonatal period262. Given the fact that LXR agonists exert 
antidiabetic effects when administered in rodents110,195, it is possible that administration 
of an LXR agonist during the neonatal period may rescue the long-term repression of 
LXR and prevent the development of programmed impaired glucose tolerance in later 
adulthood86,87. 
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While the effects of neonatal LXR agonist administration on glucose and 
cholesterol homeostasis still need to be assessed long-term, preliminary data suggest that 
LXR and other nuclear receptor agonists may play a promising role in reversing the long-
term adverse effects of impaired fetal development. However, caution must still be taken 
since LXR agonist administration does lead to the elevated expression of hepatic 
lipogenic genes203. 
 
1.8 Rationale, Hypothesis, and Objectives 
1.8.1 Rationale and Hypothesis: IUGR is now closely linked to the increased risk of 
developing chronic disease in later life44,45. A mismatch in environment, as proposed by 
the Barker Hypothesis, is responsible for the programming of these diseases58-60. 
Moreover, the concept of catch-up growth appears to exacerbate the risks of developing 
chronic diseases62,69. Yet, the molecular mechanisms underlying the programming of 
impaired glucose homeostasis, an essential symptom of the metabolic syndrome, remain 
elusive. Given the role of LXR in modulating the metabolism of glucose, lipids, and 
cholesterol, it is an attractive candidate to study in order to elucidate the molecular 
mechanisms behind the programming of diseases such as the metabolic syndrome. 
Evidence from our laboratory and others suggests that LXR expression and activity may 
be repressed in rodent models of IUGR, especially maternal protein restriction75,261,262. 
Further considering the role of LXR agonists in exerting antidiabetic effects in 
rodents110,195, there is strong evidence that LXR may be involved in the programming of 
impaired glucose metabolism. Using MPR in the rat as a model of growth restriction, I 
46 
 
hypothesize that MPR does indeed lead to impaired glucose homeostasis in the 
offspring and that impairment of glucose homeostasis is at least partly mediated 
through altered actions of LXR. 
 
1.8.2 Objectives: 
The first objective of the study is to determine the effects of MPR on impairing glucose 
homeostasis in offspring by examining glucose tolerance of offspring in adulthood. 
The second objective is to determine the role of LXR in the programming of impaired 
glucose homeostasis by examining: A) expression profiles of LXR and LXR-target genes 
involved gluconeogenesis (e.g. G6Pase, PEPCK, and 11β-HSD1); B) the active and 
repressive roles of LXR on a transcriptional level and; C) the long-term effect of 
administration of an LXR agonist (GW3965) during neonatal life, a period of 
developmental plasticity. 
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2.1 Introduction 
 Epidemiological evidence suggests that adverse events in utero (e.g. placental 
insufficiency-induced intrauterine growth restriction (PI-IUGR)) can permanently alter 
physiological processes leading to hypertension and type II diabetes1-5. Previous animal 
models of maternal protein restriction have consistently linked asymmetric IUGR6 with 
symptoms of type II diabetes long-term in the offspring. For example, Petrik et al. (1999) 
demonstrated a low protein diet during pregnancy and weaning induced a decrease in 
birth weight and disrupted pancreatic β-cell proliferation in the adult offspring7. Other 
studies have found altered glucagon-stimulated and insulin-stimulated hepatic glucose 
output as well as reduced glucokinase expression and structural modifications in the 
livers of low protein offspring8,9. In addition, Chamson-Reig et al. (2009) have 
demonstrated that low protein offspring have impaired glucose tolerance as early as 130 
days of age in rat offspring10. Thus, the evidence strongly suggests that maternal low 
protein mediated IUGR in the rat predisposes the offspring to impaired glucose tolerance 
and a type 2 diabetes-like phenotype. However, the molecular mechanisms underlying 
these low protein induced alterations in the output of hepatic glucose are not completely 
understood.    
 The liver X receptor (LXR) is a transcription factor belonging to the 1H 
subfamily of nuclear receptors. LXR exists as two isoforms: LXRα and LXRβ. LXRα is 
mainly expressed in the liver, adipose tissue, macrophages, and intestines11,12, while 
LXRβ is ubiquitously expressed13. Endogenous ligands for LXR are mainly derivatives 
of cholesterol (i.e., oxysterols)14,15. Consequently, LXR has principally been implicated 
in regulating genes involved in the metabolism and transport of cholesterol14,16 and in 
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enhancing the expression of lipogenic enzymes17. Recent studies have also demonstrated 
that LXR can silence genes involved in glucose production including 
phosphoenolpyruvate kinase (PEPCK) and glucose-6-phosphatase (G6Pase), both critical 
enzymes involved in the gluconeogenic pathway18-20. In addition, LXR has also been 
found to indirectly suppress hepatic glucose production through inhibition of the enzyme 
11β-hydroxysteroid dehydrogenase-1 (11β-HSD1)18. 11β-HSD1 reduces inactive 
corticosteroids to their active form (e.g. 11-dehydrocorticosterone to corticosterone in the 
rodent). Since active corticosteroids are responsible for increased glucose production, 
LXR-mediated inhibition of 11β-HSD1 would indirectly decrease glucose production. 
Moreover, LXR has been implicated in the regulation of the glucocorticoid receptor 
(GR), further encompassing its activity in the regulation of glucocorticoids and glucose 
homeostasis21. 
Previous studies from our own laboratory have found that maternal protein 
restriction (MPR) leads to decreases in the expression of the LXR-target gene, Cyp7a1, 
the critical enzyme involved with cholesterol catabolism. The decrease in Cyp7a1 led to 
hypercholesterolemia in male offspring by 4 months22. This was found to be due, in part, 
to repressive changes in histone modifications at the LXRE site of the Cyp7a1 promoter. 
Other studies in mice have demonstrated that MPR leads to hypermethylation of the 
LXRα promoter in association with decreased LXRα mRNA in the liver tissue of 
embryonic day 19.5 fetuses, however the effect on post-translational histone 
modifications surrounding LXRα remain elusive23. While we and others have 
demonstrated that MPR can lead to long-term epigenetic alterations of LXR-target genes 
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involved with cholesterol and lipid homeostasis, it is not known if LXR-target genes 
impairing hepatic gluconeogenesis are altered.  
 The aims of the current study were to examine whether maternal protein 
restriction alters LXRα-mediated gluconeogenesis in the liver. Given the role of LXRα in 
lipid, glucose and cholesterol homeostasis, it is an attractive candidate in elucidating the 
molecular mechanisms underlying IUGR-related fetal programming. We hypothesized 
that decreased maternal protein availability during gestation would impair hepatic 
gluconeogenesis in the adult offspring through decreases in LXRα and aberrant activity 
of its target genes (G6Pase, PEPCK, 11β-HSD1). Using a well-established model of 
maternal protein restriction in rat pregnancy, we assessed the effects of a low protein diet 
in gestation on long-term glucose handling, LXRα activity and the expression of hepatic 
LXR-target genes involved in gluconeogenesis.  In the control group, dams were fed a 
20% protein diet throughout life. Low protein dams received an 8% protein diet until 
birth of the offspring, followed by a 20% protein diet during the weaning period (until 
postnatal day 21). We decided to examine the effects of restoring protein immediately 
after birth as opposed to waiting until after the weaning period because we have already 
demonstrated earlier restoration of protein promotes accelerated catch-up growth22. 
Moreover, postnatal accelerated growth of IUGR offspring has been demonstrated to 
exacerbate the effects of IUGR-related programming and reduce the lifespans of these 
offspring24-26.            
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2.2 Materials and Methods 
 
2.2.1 Animal Experiments and Dietary Regime 
All procedures were performed in accordance with the guidelines set by the 
Canadian Council of Animal Care and upon approval of the Animal Care Committee of 
the University of Western Ontario. Male and female Wistar rats at breeding age (250 g) 
were purchased from Charles River (La Salle, St-Constant, Quebec, Canada) and were 
allowed to acclimatize to their new environment for two weeks. Rats were housed at 
room temperature on a 12-12 hour light-dark cycle. Females were housed in separate 
cages and were cohabitated with a male for mating upon entering pro-estrous. Conception 
was confirmed by presence of sperm in the vaginal smear the following day. 
Dams and offspring received isocaloric diets (Bio-Serv, Frenchtown, NJ, USA) 
varying in protein composition, depending on their experimental group. Briefly, the 
control offspring and dams received 20% protein throughout life. Protein restricted dams 
received low protein chow (8%) throughout gestation and then restored on a 20% protein 
chow immediately after birth (herein termed ‘LP’). All diets and water were administered 
ad-libitum. Previous studies by our laboratory have demonstrated that the food intake 
between both offspring groups is practically identical22.  The experimental model is 
exemplified in Figure 2.1. 
At embryonic day 19, a subset of dams (3 control dams; 4 LP dams) was 
sacrificed and livers from the fetuses were extracted. The livers were flash frozen for 
further molecular analysis. The other subset of dams (4 control dams; 4 LP dams) 
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delivered spontaneously. All litters with greater than 10 pups were arbitrarily culled 
down to 9-10 pups to ensure a consistent litter size per dam. 
 After the intraperitoneal glucose tolerance tests at postnatal day 120-125, all 
offspring were sacrificed using a lethal dose (50mg/kg) of Euthanyl forte pentobarbital 
sodium (Bimeda-MTC, Cambridge, ON, Canada) at postnatal day 130. This age was 
chosen because previous studies have demonstrated that in other models of protein 
restriction, impaired glucose tolerance was not observed earlier than 4 months10. 
Following sacrifice, liver and blood were immediately extracted and flash frozen at -80oC 
for molecular analysis. We did not examine the female offspring in this study to prevent 
confounding factors related to their estrous cycle and hormone profile. More importantly, 
the maternal low protein model has been demonstrated to exhibit early life programming 
effects in a sexually dimorphic manner, which was not the focus of this 
investigation10,22,27. For molecular analysis, one to two male pups from each of four 
separate dams were arbitrarily chosen. All available male pups were used for the 
intraperitoneal glucose tolerance tests.  
 
 
 
 
 
 
 
 
  
 
Figure 2.1: Experimental Paradigm of the Maternal Protein Restricted Model
Briefly, control (C) dams and offspring received a control (20%) diet throughout life, 
while low protein (LP) dams received a low protein (8%) diet throughout gestation. At 
birth, the LP dams were immediately placed on a control diet to restore protein
promote accelerated growth in the offspring
at the end of the weaning period
 
 
 
 
 
. Offspring of LP dams received a control diet 
 (postnatal day 21). 
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2.2.2 Glucose Tolerance Tests 
 At postnatal day 120-125, male offspring were subject to an intraperitoneal 
glucose tolerance test (IPGTT). Prior to the IPGTT, the animals were fasted overnight for 
14-16 hours. Animals were awake throughout the experiment. Blood glucose 
measurements were obtained using a Bayer Breeze® 2 Blood Glucose Meter (Bayer, New 
York, USA). Fasted blood glucose levels were obtained prior to the glucose injection. 
Animals then received 2g/kg of glucose via injection into the intraperitoneal cavity. 
Blood glucose was sampled at the tail vein at t= 0, 5, 10, 15, 30, 60, and 120 minutes. 
Area under the curve of each animal was calculated using GraphPad Prism software.  
IPGTT were performed on 6 control males and 10 LP males. 
 
2.2.3 Quantitative Real Time PCR (qRT-PCR) for Gene Expression Analysis 
 Total RNA was extracted from the medial lobe of offspring livers at embryonic 
day 19 and postnatal day 130 as previously described, using the one-step TRIzol 
(Invitrogen, Carlsbad, CA, USA) method22. Total RNA was subsequently treated with 
deoxyribonuclease to eliminate contaminating DNA. 4µg of total RNA was then reverse 
transcribed to cDNA using random primers and Superscript II RNase H-reverse 
transcriptase (Invitrogen, Carlsbad, CA, USA). Taqman® probes and sequences for the 
genes of interest (11β-HSD1, G6Pase, LXRα, PEPCK, β-Actin) and Taqman® Universal 
Master Mix were obtained from Invitrogen. Quantitative analysis of mRNA expression 
was measured using the Bio-Rad CFX384 Real Time System. The cycling conditions 
were as follows: polymerase activation (95oC for 10 minutes) followed by 40 cycles of 
denaturing (95oC for 15 seconds) and annealing (60oC for one minute). The cycle 
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threshold was set where the exponential increase in amplification was equivalent between 
all samples. Relative fold changes were calculated using the comparative cycle times (Ct) 
method with β-actin as the reference gene. ∆Ct values for each probe set were 
standardized to the experimental samples with the lowest transcript abundance (highest 
Ct value). The relative abundance of each primer set compared with calibrator was 
determined by the formula, 2∆∆Ct, where ∆∆Ct was the standardized Ct value. 
 
2.2.4 Tissue Protein Extraction and Western Immunoblotting 
 Tissue protein was extracted from the medial lobe of snap frozen offspring livers 
using a lysis buffer solution (pH 7.4, Tris-HCl 50mM, NP-40 1%, Sodium-deoxycholate 
0.25%, NaCl 150mM, EDTA 1mM, NaF 50mM, Na3VO4 1mM 1mM, β-
Glycerophosphate 25mM). Prior to tissue homogenization, a mini protease inhibitor 
tablet was added to the lysis buffer.  
Firstly, a small chunk of snap frozen liver was added to 600µl of RIPA buffer. 
The tissue was then homogenized with the IKA T10 Basic S1 Dispersing Tool (IKA 
Works Inc, Wilmington, NC) for 10-15 seconds at speed 6. After letting the homogenized 
tissue sit on ice for 5 minutes, the tissue was then sonicated. Following sonication, the 
tissue was rotated at 4oC for 5 minutes and then centrifuged for 15 minutes at 300g and 
4oC. The supernatant was retained for further centrifugation at 20,000g for 20 minutes at 
4oC. The final supernatant was retained for protein quantification and western 
immunoblotting. 
Equal concentrations of total protein were normalized using a colorimetric BCA 
Protein Assay (Pierce Corp., Madison, WI, USA). Proteins were then fractionated in 17-
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well gradient polyacrylamide gels (Invitrogen, Carlsbad, CA, USA) and transferred onto 
PVDF membrane (Millipore, Etobicoke, Ontario, Canada). Amido black staining and 
Coomassie brilliant blue staining confirmed sufficient transfer of proteins onto the 
membrane. 
Immunoblots were probed using LXRα (Liver X Receptor (1:1000; cat# sc-
13068)), PEPCK (1:2000; cat# sc-32879), G6Pase-α (1:1000; cat# sc-25840), PI3-kinase 
p85α (Z-8) (1:1000; cat# sc-423) and 11β-HSD1 (1:800; cat# sc-20175) all from Santa 
Cruz Biotechnology (Santa Cruz, California).  In addition, p-Akt1 (Serine 473) (1:1000; 
cat# ab66138), p-Akt1 (Threonine 308) (1:500; cat #4796) and Akt1 (1:125; cat# ab6076) 
antibodies used to assess hepatic insulin sensitivity, were purchased from Abcam Inc, 
Cambridge, Massachusetts. In addition, we also assessed insulin sensitivity by using 
antibodies against p-IRS-1 (Serine 302) (1:500; cat# 2384), p-IRS-1 (Serine 1101) 
(1:500; cat# 2385), and IRS-1 (1:500; cat# 2382) all purchased from Cell Signaling, 
Danvers, Massachusetts Monoclonal HRP conjugated β-Actin (1:50,000; cat#A3854, 
Sigma-Aldrich, Oakville, Ontario, Canada) diluted in 5% milk-TBS-Tween-20(0.1%) 
buffer and HRP conjugated donkey anti-rabbit IgG (1:10,000, cat# 711-035-152, Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) diluted in 5% milk-TBS-Tween-
20(0.1%) buffer were used as the secondary antibodies. Finally, immunostained bands 
were then visualized using an enhanced chemiluminescence detection system (Thermo 
Scientific, Waltham, MA, USA). 
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2.2.5 Chromatin Immunoprecipitation (ChIP) 
Chromatin was extracted from the medial lobe of offspring livers as previously 
described22. Briefly, a small piece of snap frozen liver was homogenized and incubated 
with 1% formaldehyde for 10 minutes at room temperature to cross-link proteins and 
DNA. Crosslinking was terminated by the addition of glycine (0.125M, final 
concentration). The liver tissue was washed once with cold PBS and placed in 500 µl of 
SDS lysis buffer (Millipore, Etobicoke, Ontario, Canada) with a protease inhibitor 
cocktail (Roche, Mississauga, Ontario, Canada). The lysates were sonicated on ice to 
produce sheared, soluble chromatin. The lysates were diluted ten times with the addition 
of ChIP dilution buffer (Millipore, Etobicoke, Ontario, Canada) and aliquoted to 400 µl 
amounts. Each of the aliquots was precleared with protein A/G Plus agarose beads (40 µl, 
Millipore, Etobicoke, Ontario, Canada) at 4°C for 30 minutes. The samples were 
centrifuged at 20,000g to pellet the beads, and the supernatant containing the sheared 
chromatin was placed in new tubes. The aliquots were incubated with 4 µg of antibodies 
against RNA Polyermase II (cat #05-623B, Millipore, Canada), trimethylated histone H3 
lysine 4 [K4] (cat #ab1012, Abcam, Canada), acetylated histone H3 lysine 9,14 [K9,14] 
(cat #05-399, Millipore, Canada), trimethylated histone H3 lysine 9 [K9] (cat# 07-442, 
Millipore, Canada), and ChIP-grade LXRα (cat# sc-13068x, Santa Cruz Biotechnology, 
Santa Cruz, California) at 4°C overnight. Two aliquots were reserved as ‘controls’ – one 
incubated without antibody and the other with non-immune IgG (Millipore, Etobicoke, 
Ontario, Canada). Protein A/G Plus agarose beads (60 µl) were added to each tube, the 
mixtures incubated for 1 h at 4°C and the immune complexes collected by centrifugation. 
The beads containing the immunoprecipitated complexes were washed sequentially for 5 
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minutes in wash buffer I (20 mM Tris-HCl, pH 8.1, 2 mM EDTA, 0.1% SDS, 1% Triton 
X-100, 150 mM NaCl), wash buffer II (same as I, except containing 500 mM NaCl), 
wash buffer III (10 mM Tris-HCl, pH 8.1, 1 mM EDTA, 1% NP-40, 1% deoxycholate, 
0.25 M LiCl), and in 2 × TE buffer. The beads were eluted with 250 µl elution buffer (1% 
SDS, 0.1mM NaHCO3 + 20 µg salmon sperm DNA (Sigma-Aldrich, Oakville, Ontario, 
Canada)) at room temperature. This was repeated once and eluates were then combined. 
Crosslinking of the immunoprecipitated chromatin complexes and ‘input controls’ (10% 
of the total soluble chromatin) was reversed by heating the samples at 65°C for 4 h. 
Proteinase K (15 µg, Invitrogen, Carlsbad, CA, USA) was added to each sample in buffer 
(50 mM Tris-HCl, pH 8.5, 1% SDS, 10 mM EDTA) and incubated for 1 h at 45°C. The 
DNA was purified by phenol-chloroform extraction and precipitated in EtOH overnight 
at 20°C. Samples and ‘input controls’ were diluted in 10-100 µl TE buffer just prior to 
qRT-PCR.  
Putative LXR binding sites (threshold of 0.7) on the promoters of G6Pase and 
11β-HSD1 were determined using the MatInspector software (Genomatix, Munich, 
Germany).  The MatInspector software was used to match the LXR consensus binding 
site (AGGTCA_DR-4_AGGTCA)12 with putative transcription factor binding sequences 
based on algorithms as described by Cartharius et al.28. Quantitative real-time PCR was 
employed using forward (5’-GGTCACTGCATGATCACAGG-3’) and reverse (5’-
CCTTGGAATCCAGAATGCTC-3’) primers that amplify a -35 bp to +92 bp region 
encompassing the rat G6Pase LXRE site (+22 bp to +46 bp), and forward (5’-
TTCGCCAAACTCTGACCTCT-3’) and reverse (5’-ACAGGTTTGGCCTGGAT-GT-
3’) primers that amplify a -115 bp to -7 bp region encompassing the rat 11β-HSD1 LXRE 
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site (-114 bp to -90 bp) (PE Applied Biosystems, Boston, MA, USA).  The LXRα (Gene: 
NR1H3) transcriptional start site (TSS) was found using the Ensembl Genome Browser 
(http://www.ensembl.org). Forward (5’- GGCTTCACTGGTTGATCCAT-3’) and reverse 
(5’-AGGGGGTTGATTCTTGAGGT-3’) primers were designed to amplify the -135 bp 
to +144 bp region surrounding the +1 bp TSS of LXRα. Recent evidence indicates that 
there is epigenetic regulation in the CG-rich regions of the LXRα promoter around the 
TSS in another rodent model of maternal protein restriction23. Thus, primers around the 
promoter were used to examine the binding of RNA polymerase II, acetylation of histone 
H3 [K9,14], methylation of histone H3 [K4], and trimethylation of histone H3 [K9] at the 
TSS of LXRα.  
The aforementioned constructed ChIP primers were then used in conjunction with 
Sso-Fast EvaGreen Supermix (Bio-Rad, Mississauga, Ontario, Canada) to perform qRT-
PCR. Similar to the gene expression assays, the relative abundance of the 
immunoprecipitated chromatin compared to input chromatin was determined using the 
2∆∆Ct method.  
 
2.2.6 Statistical Analysis 
 All data is represented as a mean of an arbitrary value ± Standard Error of the 
Mean (SEM). Glucose tolerance tests, areas under the curve, quantitative real-time PCR 
(including ChIP), and quantified western immunoblot bands were analyzed using the 
unpaired Student’s t-test. All data with a p-value less than 0.05 were considered 
statistically significant. 
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2.3 Results 
 
2.3.1 Maternal protein restriction with earlier protein restoration after birth leads 
to liver and body weight catch up growth by 3 weeks of age 
 
As previously reported, at embryonic day 19, the LP animals exhibited significantly 
decreased fetal to placental weight ratios compared to the control animals (Control: 
5.67±0.30; LP: 4.87±0.18; p<0.05), indicating growth restriction22. Furthermore, liver 
weight to body weight ratios were decreased in the LP animals (Control: 0.091±0.004; 
LP: 0.056±0.006; p<0.05), indicating hepatic growth restriction at embryonic day 19. 
However, by 3 weeks of age, the LP male offspring caught up to the control offspring in 
terms of body weight (Control: 50.30±1.15g; LP: 48.00±2.17g)22. Similarly, there were 
no significant differences in the liver weight to body weight ratios between the LP 
animals and control animals at 3 weeks of age (Control: 0.0391±0.001; LP: 
0.0360±0.001)22, indicating recovered liver growth. At 4 months of age, these patterns 
continued and there were no differences in body weight (Control: 565.50±8.21g; LP: 
579.00±18.74g) or liver weight to body weight ratios (Control: 0.0314±0.001; LP: 
0.0306±0.001) between the control and LP offspring22. There were 10-14 offspring per 
experimental group.  
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2.3.2 Maternal protein restriction leads to impaired glucose tolerance at 4 months of 
age in male offspring 
 
At 4 months of age, all of the male offspring underwent an IPGTT to assess fasted 
glucose tolerance after an administered glucose load. Resting levels of glucose were not 
significantly different between control and LP animals. After administration of the 
glucose (2g/kg), measured blood glucose levels were significantly elevated (p<0.05) in 
LP animals at the 10-, 15-, 30-, and 60-minute time points (Figure 2.2A). Blood glucose 
levels in the LP animals returned to the same levels as the control animals by the 120-
minute time point. At the end of the experiment, both control and LP animals had similar 
blood glucose levels. The area under the curve for the LP animals was increased by 
32.8% (p<0.05) compared to the control animals (Figure 2.2B) further indicating 
impaired glucose tolerance at 4 months of age. Although we did not perform insulin 
tolerance tests, hepatic insulin sensitivity was assessed through western immunoblot 
detection of phosphorylated-Akt1 (S473 and T308), the p85 subunit of phosphoinositide 
3-kinase (p85), and phosphorylated IRS-1 (S302 and S1101), all markers of insulin 
sensitivity29,30. Protein expression of these proteins was unchanged between control and 
LP animals, suggesting no difference in insulin sensitivity between the experimental 
groups at 4 months of age (Figure 2.3). 
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2.3.3 The steady-state levels of hepatic LXRα mRNA are decreased, concomitant 
with an increase in G6Pase and 11β-HSD1 mRNA in LP animals by 4 months of age 
 
Given the LP animals exhibited glucose intolerance at 4 months of age, we subsequently 
investigated the expression of hepatic LXRα and its target genes involved in 
gluconeogenesis. To determine differences in the in vivo hepatic mRNA levels of LXRα, 
G6Pase, 11β-HSD1, and PEPCK at 4 months of age in the male offspring, qRT-PCR was 
employed with Taqman® probes for each gene. LXRα mRNA was significantly decreased 
by 45% (p<0.05) in the LP offspring, while PEPCK mRNA was unchanged between 
groups (Figure 2.4). Hepatic G6Pase and 11β-HSD1 mRNA were significantly increased 
(p<0.05, 1.6 fold) in the LP offspring (Figure 2.4).  
 
2.3.4 The levels of hepatic LXRα protein are decreased, concomitant with an 
increase in G6Pase, 11β-HSD1 and GR protein levels in LP animals by 4 months of 
age 
 
To assess the effect of a maternal low protein diet on the protein levels of LXRα and 
LXR-target genes in 4-month-old offspring, we performed western immunoblotting to 
determine if there would be similar trends to what was observed in the steady-state 
mRNA levels. At 4 months of age, LXRα protein expression was decreased by 40% 
(p<0.05), while both G6Pase and 11β-HSD1 protein levels were increased (p<0.05, 1.5 
and 1.6 fold, respectively) in the LP animals compared to the control animals (Figure 
2.5).  PEPCK protein expression was not different between the two groups. We also 
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investigated the protein expression of GR since we saw increases in the expression of 
11β-HSD1. GR protein expression increased in LP offspring compared to control 
offspring (p<0.05, 1.3 fold). 
 
2.3.5 LXRα binding to the LXRE on the promoters of G6Pase and 11β-HSD1 is 
decreased by 4 months of age in the LP offspring 
 
To investigate whether the changes in the expression of G6Pase and 11β-HSD1 between 
the control and LP offspring were due to the decreased binding of LXRα to the promoters 
of G6Pase and 11β-HSD1, we employed ChIP to immunoprecipitate LXRα. After using 
MatInspector (Genomatix, Munich, Germany) to find putative LXREs on the promoters 
of G6Pase and 11β-HSD1, qRT-PCR was employed to examine LXRα binding at these 
putative LXRE sites. By 4 months of age, the LP animals exhibited a marked decrease in 
the binding of LXRα to the promoter of 11β-HSD1 (45% decrease) and G6Pase (50% 
decrease) compared to the control animals (p<0.05) (Figure 2.6). The non-specific 
binding of immunoglobulin G (IgG) was tested and found to be minimal (Ct value > 34, 
data not shown). 
 
2.3.6 Acetylation of lysine residues 9 and 14 on histone H3 is decreased surrounding 
the transcriptional start site of LXRα in LP offspring by 4 months of age 
 
We further employed ChIP to examine the epigenetic regulation of LXRα at its TSS. By 
immunoprecipitating chromatin with antibodies specific to RNA polymerase II, 
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trimethylated histone H3 [K9], acetylated histone H3 [K9,14], and trimethylated histone 
H3 [K4] we were able to examine the transcriptional and epigenetic regulation of LXRα 
in our model of maternal protein restriction. Using primers specific to the -144 to +134 
region of the LXRα gene promoter and qRT-PCR, we found a significant 45% reduction 
(p<0.05) in the acetylation of histone H3 [K9,14], a hallmark of chromatin silencing, near 
the TSS of LXRα (Figure 5C). While not significant, we also found a decreasing trend in 
the recruitment of RNA polymerase II binding and histone H3 trimethylation [K4] at the 
same site (Figures 2.7A and 2.7B). Again, the non-specific binding of IgG was tested and 
found to be minimal (Ct value > 34, data not shown). These results, in combination, 
support the notion that LXRα is transcriptionally and epigenetically silenced long-term in 
our maternal protein restriction model of IUGR. 
 
2.3.7 The steady-state levels of hepatic LXRα mRNA are unchanged between 
control and LP offspring concomitant with a decrease in G6Pase and 11β-HSD1 
mRNA in LP animals at embryonic day 19 
 
To assess the direct effects of the LP diet on LXRα and LXR-target gene expression 
during gestation and prior to birth, we analyzed the livers of fetuses sacrificed at 
embryonic day 19. Quantitative real-time PCR was employed with Taqman® probes for 
LXRα, G6Pase and 11β-HSD1 (PEPCK could not be detected in our embryonic liver 
tissue). At embryonic day 19, there were no differences in LXRα mRNA expression 
between the control and LP animals. However, both G6Pase and 11β-HSD1 mRNA 
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expression was decreased in LP offspring compared to control offspring (p<0.05) (Figure 
2.8).  
  
  
 
Figure 2.2: A) Intraperitoneal glucose tolerance tests (2g/kg) administered to fasted male 
offspring at 4 months of age. Control and LP animals were analyzed together at each time 
point (t=0, 5, 10, 15, 30, 60, 120 minutes) using the 
under the curve of Control and LP animals. Area under the curve was calculated using 
GraphPad Prism software. (Control n=6, LP n=10). Results are expressed as the mean 
standard error (SEM). * = Statistically significant (p<0.05).
 
 
 
 
 
 
 
 
 
Student’s unpaired t-
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Figure 2.4: The effect of LP on 
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Figure 2.5: The effect of LP on the 
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Figure 2.6: The effect of LP on the 
A) G6Pase (+22 bp to +46 bp) and 
offspring at 4 months of age. Putative LXRE sites were determined using
MatInspector software from 
antibodies specific to LXRα
EvaGreen) with primers specific to the proposed LXRE sites. The relative amount of 
immunoprecipitated genomic DNA was normalized to total genomic DNA. Data are 
represented as arbitrary values using the 
+ standard error (SEM). * = Statistically significant. n=4
 
 
 
 
 
in vivo hepatic binding of LXRα to the promoters of 
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Figure 2.8: The effect of LP on 
mRNA, C) 11β-HSD1 mRNA in control and LP offspring at embryonic day 19. Data 
were quantified from qRT-PCR (
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2.4 Discussion 
 
Our current study demonstrates that male offspring of LP dams exhibit increased 
expression of hepatic gluconeogenic genes due to aberrant expression of hepatic LXRα. 
This is of great interest considering previous studies have indicated that maternal protein 
restriction leads to glucose dysregulation8-10. We present evidence for the first time that 
suppressed expression of LXRα may mediate the enhanced transcription of the 
gluconeogenic genes G6Pase and 11β-HSD1 due to its decreased binding on these 
promoters, ultimately removing its ability to suppress hepatic gluconeogenesis18,19,31,32.  
Given placental insufficiency in humans can produce protein deficiency in the 
fetus33, this LP model shares features in common with PI-IUGR34. Previous studies done 
in our lab with the same cohort of animals have already demonstrated that LP offspring 
exhibit a 15% lower fetal to placental weight ratio and a 40% decreased fetal liver to 
body weight ratio at embryonic day 1922. While switching the low protein offspring to a 
control diet at weaning led to glucose intolerance10, little is known about how catch-up 
growth due to early restoration of protein22 influences their hepatic glucose handling by 
adulthood. In our LP model, after switching to a control (20% protein) diet at birth, the 
animals exhibited full catch-up growth by 3 weeks of age22. Moreover, by 4 months, 
these offspring exhibited impaired glucose tolerance with no evidence of hepatic insulin 
insensitivity. Given that glucose intolerance precedes insulin resistance, it is likely that 
these MPR offspring will develop insulin resistance at a later time point. Interestingly, 
the impaired glucose tolerance was similar, not worse, to low protein offspring at 4 
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months whereby their diet was switched to 20% at weaning10. Collectively, both studies 
further support of the main tenets of the Thrifty Phenotype hypothesis35. 
We previously found that LXRα expression and binding could be influenced by 
maternal diet by 3 weeks of age in the offspring22, but the expression of LXRα at 4 
months was unknown. In this study we demonstrated that in LP offspring, hepatic LXRα 
mRNA and protein was decreased at 4 months of age compared to control offspring. 
Interestingly, even though LXR expression was decreased in our LP animals, previous 
plasma analyses indicate no differences in the levels of circulating cholesterol and 
triglycerides in the same cohort of animals22. Given aberrant LXRα expression and 
activity can alter the expression of genes involved in hepatic gluconeogenesis (e.g. 
PEPCK, G6Pase, and 11β-HSD1)18-20,32, we next examined whether the expression of 
these LXR-target genes was altered in LP offspring. At 4 months, we found increases in 
the steady-state mRNA and protein levels of G6Pase in LP male rats. This is of great 
interest considering that this LXR-target gene is responsible for the final catalytic step of 
gluconeogenesis, the conversion of glucose-6-phosphate to glucose. Moreover, 
overproduction of G6Pase does not necessarily lead to increases in fasting glucose levels, 
but it does lead to an enhanced glucose response (e.g. a greater area under the curve 
during glucose tolerance tests), both of which we also observed36. To directly implicate 
whether alterations in LXRα expression influenced the binding of LXRα to the promoter 
of G6Pase, we then employed chromatin immunoprecipitation to examine the in vivo 
binding of LXRα to its a putative LXRE on the promoter of G6Pase. At 4 months of age, 
we observed a decrease in the binding of LXRα to the LXRE site (+22 to +46) of the 
G6Pase promoter. These data suggests that the increase of G6Pase expression seen in 
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protein restricted offspring is at least partly due to the decreased binding of LXRα to the 
putative G6Pase promoter. Overexpression of PEPCK has also been demonstrated to 
impair glucose tolerance and lead to non-insulin-dependent diabetes37, however we did 
not find any significant alterations in PEPCK mRNA or protein. This is in contrast to 
other studies whereby hepatic PEPCK activity increased in 3-week-old and 11-month-old 
offspring fed a low protein diet during gestation38, and low protein offspring fed a high 
sucrose diet (500 g/kg) postpartum39. The difference in the former study may be due to 
the fact that the offspring were cross-fostered to dams not subjected to a low protein diet, 
potentially leading to even greater catch-up growth.  
Dysregulation of glucocorticoids may also play a role in impairing glucose 
homeostasis in our LP model. Our study demonstrated an increase in 11β-HSD1 mRNA 
along with elevated 11β-HSD1 protein levels in the LP offspring. In addition, we found 
increases in protein expression of the glucocorticoid receptor, GR. Interestingly, while 
previous nutrient restriction models have demonstrated no change in 11β-HSD1 
expression in the adipose tissue of adult rat offspring40, its expression in the liver was not 
examined. Similar to G6Pase, we proposed that a decrease in LXRα expression and 
binding would lead to the loss of inhibitory action on the 11β-HSD1 promoter and a 
subsequent increase in 11β-HSD1 gene expression. Our ChIP experiments confirmed our 
speculation by demonstrating a decrease in LXRα binding to the putative LXRE (-114 to 
-90) on 11β-HSD1. With increased expression of 11β-HSD1, it is conceivable that there 
would be enhanced conversion of inactive glucocorticoids to active glucocorticoids. 
Furthermore, the increased expression of GR also indicates induction of glucocorticoid 
activity. Previous reports have found GR response elements on the promoter of 
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G6Pase41,42, suggesting dual regulation of the G6Pase promoter by GR and LXR. As 
well, LXR induction has been demonstrated to inhibit GR expression21. Since 
glucocorticoids have stimulatory effects on the expression of gluconeogenic genes such 
G6Pase and PEPCK41,43,44, the sustained overproduction of glucocorticoids would lead to 
an augmented glucose response, as observed in the IPGTT. Collectively, it is likely that 
the overproduction of G6Pase may not only occur due to the direct actions of LXRα, but 
also indirectly through enhanced 11β-HSD1 and GR expression. 
 Previous studies strongly suggest the role of epigenetics in mediating the effects 
of fetal programming long-term into adulthood39,45-48. By 4 months of age, we 
demonstrated that LP males exhibited significantly decreased acetylation of histone H3 
[K9,14] associated with trends of decreased RNA polymerase II recruitment and 
decreased methylation of histone H3 [K4] surrounding the promoter of LXRα. 
Considering acetylation of histone H3 [K9,14] and methylation of histone H3 [K4] are 
both known to hallmarks of chromatin opening49-51, our findings suggest that the LXRα 
TSS is silenced through epigenetic mechanisms by adulthood. These findings are 
congruent with the decreased levels of LXRα mRNA and protein expression observed. 
Additionally, we previously demonstrated that MPR leads to long-term decreases in 
histone H3 acetylation [K9,14] surrounding the promoter of the LXR-target gene 
Cyp7a1, resulting in hypercholesterolemia in these offspring22. To address whether the 
low protein diet itself directly alters hepatic LXRα and LXR-target genes in vivo, we 
measured their fetal expression (embryonic day 19) during the low protein insult. 
Interestingly, the low protein diet impaired these hepatic genes involved in 
gluconeogenesis without changes to LXRα expression. This suggests that the augmented 
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expression of LXRα, G6Pase and 11β-HSD1 observed in adulthood is more likely due to 
the indirect actions of the low protein diet, namely, a protein mismatch in postnatal life 
associated with rapid catch-up growth.  
In view of the fact that LXRα suppresses glucose production, it may be a suitable 
target as a therapeutic intervention to prevent glucose intolerance. Animal studies have 
widely demonstrated that administration of LXR agonists (i.e. GW3965, T0901317) lead 
to improved glucose tolerance19,32. Given that during the newborn period in the rat there 
is a high rate of replication, neogenesis and apoptosis leading to extensive liver 
remodeling52, this period represents a critical, but opportune window for therapy 
designed to improve hepatic growth and function long-term. For example, it has been 
demonstrated in IUGR rats derived from uterine artery ligated dams, that neonatal 
administration of Exendin-4™ (a GLP-1 analog) prevented the development of hepatic 
oxidative stress and insulin resistance53. Therefore it is plausible that LXRα agonists, 
administered in neonatal life, a period of liver plasticity, may prevent glucose intolerance 
long-term through activation of hepatic LXRα.  While LXR agonists appear promising, 
the negative effects of LXRα activation must also be considered given it can activate 
lipogenesis through increased expression of fatty acid synthase (FAS), acetyl-CoA 
carboxylase (ACC) and the master lipid regulator, sterol regulatory element binding 
protein-1c (SREBP-1c)54.  
In summary, our study demonstrates for the first time the role of LXRα in 
mediating the transcriptional regulation of hepatic gluconeogenic genes in our rat LP 
model. In these offspring, decreased expression of hepatic LXRα reduced the 
transcriptional inhibition of hepatic G6Pase and 11β-HSD1. This increased expression of 
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G6Pase and 11β-HSD1 in LP offspring would contribute, in part, to the aberrant glucose 
handling observed in these animals.  Given the role of hepatic LXRα in reducing glucose 
production, it serves as a possible therapeutic target of intervention due to its antidiabetic 
properties. Further studies will be necessary to find a suitable balance between 
antidiabetic and lipogenic actions of LXRα before it could be considered as an ideal 
candidate for preventing glucose intolerance in IUGR offspring. 
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Chapter Three: 
Administration of the Liver X Receptor Agonist GW3965 During the Neonatal 
Period Leads to Impaired Glucose Tolerance in Non-Maternal Protein Restricted 
Adult Male Rats 
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3.1 Introduction 
 Epidemiological studies have indicated a strong connection between impaired 
development and growth in utero and the risk of developing chronic diseases1,2. Low 
birth weight infants are often a result of intrauterine growth restriction (IUGR). The 
“Thrifty Phenotype Hypothesis” postulates that during gestation the fetus programs itself 
for short-term survival in utero, and that these adaptations become maladaptive in 
postnatal life due to a mismatch in the environments3,4. These maladaptive changes may 
have detrimental effects on the individual in later life by increasing their risk of 
developing cardiovascular disease, hypertension, obesity, and type 2 diabetes5-9.  
 The maternal protein restriction (MPR) model of IUGR is a well-studied model 
for examining the developmental origins of health and disease. Typically, in models of 
MPR the mother is given a low protein diet (5-8%) during the gestation period (and often 
the weaning period). Previous studies have demonstrated that MPR leads to impaired 
glucose homeostasis, impaired pancreatic development and function and altered hepatic 
function in the offspring10-14. Other studies have also found detrimental effects in the 
kidneys and heart, in addition to changes in the longevity of MPR offspring15-18. Studies 
from our own lab have found elevated cholesterol in MPR offspring due to altered 
epigenetic regulation of the Cyp7a1 gene19. More recently, our lab has uncovered that 
MPR during gestation (and not weaning) leads to suppressed Liver X Receptor (LXR) 
expression, facilitating the transcriptional induction of glucose-6-phosphatase (G6Pase) 
and 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) in male MPR offspring. These 
findings implicate LXR as a key factor in mediating the detrimental programming effects 
of IUGR20. 
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 LXR is a nuclear receptor that exists as two isoforms: LXRα and LXRβ. LXRα is 
generally found in the liver, intestines, adipose tissue and macrophages21,22, while LXRβ 
is expressed ubiquitously23. LXR was first implicated in the regulation of cholesterol 
metabolism since its endogenous ligands were mainly derivatives of cholesterol24,25. 
Furthermore, LXR has been connected to lipid metabolism by stimulating the expression 
of many lipogenic genes including sterol regulatory element binding protein-1 (SREBP-
1), fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), and stearoyl-CoA 
desaturase-1 (SCD-1)26-30. More recently, LXR has been found to be able to bind glucose 
and act as a glucose sensor31. In addition, LXR has demonstrated the ability to 
downregulate genes involved in the gluconeogenic pathway such as phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase32,33. Finally, LXR has been 
associated with glucocorticoid regulation through repression of 11β-HSD1, an essential 
enzyme involved in the conversion of inactive glucocorticoids to their active form.  
 Studies have been exploring the possibility of intervening during the neonatal 
period to reverse the programming observed in IUGR offspring. Certain organs like the 
liver and pancreas continue to develop even after birth and display great plasticity, 
especially in rodents34,35. Given that there is still a great deal of hepatic and pancreatic 
neogenesis, differentiation, replication, and apoptosis during the early neonatal period, it 
represents a critical time point for possible intervention34,36. For instance, in an elegant 
study done by Stoffers and colleagues (2006), administration of the glucagon-like 
peptide-1 (GLP-1) analogue Exendin-4™ during the neonatal period completely 
prevented the development of diabetes in uterine artery ligated IUGR rats37. They 
postulate that this change is mediated through restoration of the pancreatic and duodenal 
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homeobox 1 protein (Pdx-1), an essential transcription factor required for pancreatic 
development and β-cell maturation37,38. Further studies done by the Raab and colleagues 
(2009) found that administration of Exendin-4™ during the neonatal period prevented 
hepatic insulin resistance and reduced hepatic oxidative stress39. Thus, these studies 
demonstrate how a short-term intervention during the neonatal period can permanently 
alter organ function in adult life.  
 Given that LXR has been demonstrated to improve glucose tolerance33,40 and our 
lab has previously implicated reduced LXR expression in partly mediating the effects of 
impaired glucose homeostasis and overexpression of gluconeogenic genes in MPR male 
adult rat offspring20, we attempt in this study to prevent the development of impaired 
glucose homeostasis in later life (4 months of age) by administering the LXR agonist 
GW3965 during the early neonatal period. In this experimental paradigm, where the MPR 
dams receive the low protein diet during both gestation and weaning (herein termed the 
“LP2” experimental group), no changes in glucose homeostasis were found between 
control and MPR diet offspring. However, in the control diet offspring, administration of 
the LXR agonist during the neonatal period led to impaired glucose homeostasis. This 
impaired glucose homeostasis was accompanied by increased gluconeogenic gene 
expression (G6Pase, PEPCK) and increased lipogenic gene expression (SCD-1). 
Furthermore these offspring displayed signs of hyperinsulinemia and 
hypertriglyceridemia in addition to the observed hyperglycemia, which all encompass 
features of the metabolic syndrome41.  
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3.2 Materials and Methods 
 
3.2.1 Animal Experiments and Dietary Regime 
All procedures were performed in accordance with the guidelines set by the 
Canadian Council of Animal Care and upon approval of the Animal Care Committee of 
the University of Western Ontario. Male and virgin female Wistar rats at breeding age 
(250 g) were purchased from Charles River (La Salle, St-Constant, Quebec, Canada) and 
were allowed to acclimatize to their new environment for two weeks. Rats were housed at 
room temperature on a 12-12 hour light-dark cycle. Females were housed in separate 
cages and were cohabitated with a male for mating upon entering pro-estrous. Conception 
was confirmed under a microscope by presence of sperm in the vaginal smear the 
following day. 
Dams and offspring received isocaloric diets (Bio-Serv, Frenchtown, NJ, USA) 
varying in protein composition, depending on their experimental group. The “control” 
offspring and dams (C-V and C-GW) received 20% protein throughout life, while 
“protein restricted” dams (LP2-V and LP2-GW) received low protein chow (8%) 
throughout gestation and then restored on a 20% protein chow after the weaning period 
(21 days after birth) (Figure 3.1). All offspring were allowed to feed on the control diet 
ad-libitum after the weaning period. 
Beginning at postnatal day 5, pups received daily intraperitoneal injections of 
25mg/kg of the LXR agonist GW3965 (LP-GW and C-GW) or equal volume of the 
vehicle DMSO (LP2-V and C-V). The pups received daily injections of the LXR agonist 
or vehicle until postnatal day 15 (Figure 3.1). In our initial experiments, where the LP2-
110 
 
pups received 50mg/kg of the LXR agonist, a subset of pups (4 LP2-V pups and 6 LP2-
GW pups) was sacrificed at postnatal day 21 and livers from the pups were extracted. The 
livers were flash frozen for further molecular analysis. All further litters with greater than 
10 pups were arbitrarily culled down to 9-10 pups to ensure a consistent litter size per 
dam. In total, there were two dams for each experimental group (8 dams total) with 9-10 
pups per litter. 
 After intraperitoneal glucose tolerance tests at postnatal day 120-125, all offspring 
were sacrificed using a lethal dose (50mg/kg) of Euthanyl forte pentobarbital sodium 
(Bimeda-MTC, Cambridge, ON, Canada) at postnatal day 130. This age was chosen 
because previous studies have demonstrated that in other models of protein restriction, 
impaired glucose tolerance was not observed earlier than 4 months42. Following sacrifice, 
liver and blood were immediately extracted and flash frozen at -80oC for molecular 
analysis. We did not examine the female offspring in this study to prevent confounding 
factors related to their estrous cycle and hormone profile. More importantly, the maternal 
low protein model has been demonstrated to exhibit early life programming effects in a 
sexually dimorphic manner, which was not the focus of this investigation19,42,43. For 
molecular analysis, at least one to two male pups from each of two separate dams were 
arbitrarily chosen.  All available male pups were used for the intraperitoneal glucose 
tolerance tests.  
 
 
 
 
  
 
Figure 3.1: Experimental Paradigm 
Receptor Agonist GW3965 in Non
dams were given a control (20% protein) diet throughout life. Control offspring also 
received a control diet after weaning (postnatal day
received a low protein (8% protein) diet throughout gestation and the weaning period. 
Low protein offspring (LP2)
animals received the vehicle DMSO during postnatal days 
(GW) received GW3965 during postnatal days 5
approximately 4 months of age (postnatal day 130). 
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3.2.2 Glucose Tolerance Tests 
 At postnatal day 120-125, male offspring were subject to an intraperitoneal 
glucose tolerance test (IPGTT) as previously described20. Prior to the IPGTT, the animals 
were fasted overnight for 14-16 hours. Animals were awake throughout the experiment. 
Blood glucose measurements were obtained using a Bayer Breeze® 2 Blood Glucose 
Meter (Bayer, New York, USA). Fasted blood glucose levels were obtained prior to the 
glucose injection. Animals then received 2g/kg of glucose via injection into the 
intraperitoneal cavity. Blood glucose was sampled at the tail vein at t= 0, 5, 10, 15, 30, 
60, and 120 minutes. Area under the curve for each animal was calculated using 
GraphPad Prism software.  IPGTTs were performed on 5 LP2-V, 7 LP2-GW, 4 C-V, 
and 8 C-GW male rats.  
 
3.2.3 Plasma Assays for Fasted Resting Blood Triglyceride and Insulin Levels 
 At 4 months of age, blood was collected from sacrificed animals and transferred 
to tubes containing EDTA. The blood was then centrifuged and plasma was collected and 
stored at -20oC until analysis. At time of analysis, samples were thawed and triglyceride 
levels were measured using the Cobas® Trig/GB colorimetric enzymatic kit (Roche 
Diagnostics, Laval, Canada). Insulin levels were measured using the ALPCO™ Insulin 
(Rat) ELISA kit (ALPCO Diagnostics, Salem, New Hampshire, USA). The 
manufacturer’s instructions were followed for both kits.   
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3.2.4 Tissue Protein Extraction and Western Immunoblotting 
 Protein extraction and western immunoblotting protocols have been previously 
described19,20. 
Tissue protein was extracted from the medial lobe of snap frozen offspring livers 
using a lysis buffer solution (pH 7.4, Tris-HCl 50mM, NP-40 1%, Sodium-deoxycholate 
0.25%, NaCl 150mM, EDTA 1mM, NaF 50mM, Na3VO4 1mM 1mM, β-
Glycerophosphate 25mM). Prior to tissue homogenization, a mini protease inhibitor 
tablet was added to the lysis buffer.  
Firstly, a small chunk of snap frozen liver was added to 600µl of RIPA buffer. 
The tissue was then homogenized with the IKA T10 Basic S1 Dispersing Tool (IKA 
Works Inc, Wilmington, NC) for 10-15 seconds at speed 6. After letting the homogenized 
tissue sit on ice for 5 minutes, the tissue was then sonicated. Following sonication, the 
tissue was rotated at 4oC for 5 minutes and then centrifuged for 15 minutes at 300g and 
4oC. The supernatant was retained for further centrifugation at 20,000g for 20 minutes at 
4oC. The final supernatant was retained for protein quantification and western 
immunoblotting. 
Equal concentrations of total protein were normalized using a colorimetric BCA 
Protein Assay (Pierce Corp., Madison, WI, USA). Proteins were then fractionated in 12-
well gradient polyacrylamide gels (Invitrogen, Carlsbad, CA, USA) and transferred onto 
PVDF membrane (Millipore, Etobicoke, Ontario, Canada). Amido black staining and 
Coomassie brilliant blue staining confirmed sufficient transfer of proteins onto the 
membrane. 
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Immunoblots were probed using LXRα (Liver X Receptor (1:1000; cat# sc-
13068)), PEPCK (1:2000; cat# sc-32879), G6Pase-α (1:1000; cat# sc-25840), 11β-HSD1 
(1:800; cat# sc-20175), and SREBP-1c (1:1000; cat# sc-366) all from Santa Cruz 
Biotechnology (Santa Cruz, California). In addition, FAS (1:1000; cat# 3180S) and ACC 
(1:1000; cat# 3662S) antibodies were obtained from Cell Signaling (Danvers, 
Massachusetts) and SCD-1 (1:1000; cat# Ab-19862) antibodies were obtained from 
Abcam Inc., Massachusetts. Monoclonal HRP conjugated β-Actin (1:50,000; cat#A3854, 
Sigma-Aldrich, Oakville, Ontario, Canada) diluted in 5% milk-TBS-Tween-20 (0.1%) 
buffer and HRP conjugated donkey anti-rabbit or donkey anti-mouse IgG (1:10,000, cat# 
711-035-152 and 715-035-150, respectively, Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA) diluted in 5% milk-TBS-Tween-20(0.1%) buffer were used as the 
secondary antibodies. Finally, immunostained bands were then visualized using an 
enhanced chemiluminescence detection system (Thermo Scientific, Waltham, MA, 
USA). 
 
3.2.5 Statistical Analysis 
 All data are represented as a mean of an arbitrary value ± Standard Error of the 
Mean (SEM), unless indicated as raw values. Glucose tolerance tests, areas under the 
curve and metabolic data were analyzed using a one-way ANOVA followed by Tukey’s 
post-hoc test. Quantified western immunoblot bands were analyzed using the unpaired 
Student’s t-test. All data with a p-value less than 0.05 were considered statistically 
significant. 
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3.3 Results 
 
3.3.1 Neonatal Administration of the LXR Agonist GW3965 Leads to Altered 
Hepatic Expression of 11β-HSD1 and SREBP-1c at Postnatal Day 21 in MPR Male 
Rat Offspring 
 
 Initially, we used a small cohort of pups to determine whether neonatal 
administration of GW3965 would lead to changes that would persist beyond the 
administration period (postnatal days 5-15). Thus, we culled 4 LP2-V pups and 6 LP2-
GW pups at postnatal day 21, one week after the administration period, and examined the 
expression of LXR-target genes via western immunoblotting. There were no changes in 
protein expression of LXR, G6Pase, or PEPCK at this time point in these animals 
(Figures 3.2 A,B&D). At postnatal day 21, even after the administration of GW3965 had 
halted, we found a significant reduction in the protein expression of 11β-HSD1, which is 
negatively regulated by LXR (p<0.05) (Figure 3.2C). In addition, we also found a 
significant increase in the protein expression of SREBP-1c, a protein that is positively 
regulated by LXR (p<0.05) (Figure 3.2E). Thus, given that there were expression changes 
in certain LXR target genes even after the administration of the LXR agonist GW3965 
was halted, we were encouraged to continue another cohort of animals that included a 
“control” diet group (C-V and C-GW).  
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3.3.2 Neonatal Administration of the LXR Agonist GW3965 Does not Alter Whole 
Body Weight or Wet Liver Weights at 4 Months of Age 
  
At postnatal day 130, the animals were sacrificed and weighed. After the whole 
body weights were weighed, the liver was extracted and weighed. The C-GW males were 
significantly heavier than LP2-V animals at 4 months of age (p<0.05) (Figure 3.3A). 
There were no differences in weight between any other groups. However, there appeared 
to be a trend where the control diet offspring were heavier than low protein diet offspring. 
For wet liver weights, LP-V liver weights were significantly less than both C-V and C-
GW experimental groups (p<0.05) (Figure 3.3B). LP-GW liver weights were also 
significantly less than C-GW liver weights (p<0.05). Again, there appeared to be a trend 
where the control diet animals exhibited increased liver weights compared to low protein 
animals. 
 
3.3.3 Neonatal Administration of the LXR Agonist GW3965 Leads to Impaired 
Glucose Homeostasis in Control Male Offspring 
  
Intraperitoneal glucose tolerance tests were administered to the offspring at 
postnatal days 120-125 to assess whole body glucose handling in response to a glucose 
load. At the 60-minute time point the C-GW animals displayed significant hyperglycemia 
versus all of the other groups (p<0.05) (Figure 3.4A). At the 120-minute time point the 
C-GW animals displayed significant hyperglycemia only against the LP2-V experimental 
group (p<0.05).  
117 
 
The areas under the curve of each animal were determined using GraphPad 
Prism software and then statistically analyzed as a gross assessment of glucose 
tolerance. The areas under the curve for C-GW offspring were significantly increased 
compared to all other groups (p<0.05) (Figure 3.4B). This suggests that the C-GW 
offspring were glucose intolerant compared to the rest of the experimental groups. 
 
3.3.4 Neonatal Administration of the LXR Agonist GW3965 Leads to Fasting 
Hyperglycemia, Hyperinsulinemia and Hypertriglyceridemia in Non-MPR (C-GW) 
Male Offspring 
  
In the control diet animals, administration of GW3965 led to significant elevation 
of fasting blood glucose levels (as assessed prior to the IPGTT) (Figure 3.5A). Fasted 
insulin levels in the C-GW experimental group were significantly elevated compared to 
both LP2-V and LP2-GW experimental groups (p<0.05) (Figure 3.5B). Only C-GW 
fasted triglycerides were significantly elevated compared to LP2-V and LP2-GW animals 
(p<0.05) (Figure 3.5C). 
 Given the results observed in our plasma analyses and glucose tolerance tests, we 
decided to exclusively pursue the molecular mechanisms underlying the detrimental 
effects of neonatal GW3965 administration in control diet (20% protein diet) animals 
only. There was a strong rationale to examine these animals since they displayed signs of 
impaired glucose tolerance (Figures 3.4A&B), fasted hyperglycemia (Figure 3.5A), 
hyperinsulinemia (Figure 3.5B), and phypertriglyceridemia (Figure 3.5C) – all of which 
encompass symptoms of the metabolic syndrome41.  
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3.3.5 Neonatal Administration of the LXR Agonist GW3965 Leads to Increased 
Protein Expression of Gluconeogenic Genes in Non-MPR Male Offspring at 4 
Months of Age 
  
To assess whether the impaired glucose tolerance observed in C-GW animals was 
due to the increased expression of gluconeogenic genes, we employed western 
immunoblotting with antibodies specific to G6Pase and PEPCK, both LXR-target genes. 
We also examined the expression of 11β-HSD1 to observe whether these changes in 
circulating glucose were indirectly related to alterations in bioactive glucocorticoid 
production. At 4 months of age, neonatal administration of GW3965 in non-MPR (C-
GW) rats led to significantly increased expression of the gluconeogenic genes, PEPCK 
and G6Pase (p<0.05) (Figures 3.6B&C). In addition, there was a significant increase in 
the expression of 11β-HSD1 (p<0.05), indicating the possibility of increased 
glucocorticoid conversion (Figure 3.6D). Interestingly, there were no changes in LXR 
expression between C-V and C-GW animals (Figure 3.6A).  
 
3.3.6 Neonatal Administration of the LXR Agonist GW3965 Leads to Increased 
Protein Expression of the Lipogenic Gene SCD-1 in Non-MPR Male Offspring at 4 
Months of Age 
 
Given C-GW animals exhibited increased circulating triglycerides (Figure 3.5C) 
we next decided to examine the protein expression of genes involved in hepatic de novo 
lipogenesis. We measured the expression of SREBP-1, FAS, ACC, and SCD-1 using 
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western immunoblotting. At 4 months of age, we found significantly elevated protein 
expression of SCD-1 in C-GW animals compared to C-V animals (p<0.05) (Figure 3.7D). 
There were no significant differences in any of the other hepatic lipogenic genes (Figures 
3.7 A-C).  
 
 
 
 
 
 Figure 3.2: The effect of neonatal GW3965 administration (50mg/kg) on the 
hepatic levels of A) LXRα protein (50 kDa), B) PEPCK protein (62 kDa), C) G6Pase 
protein (36 kDa), D) 11β-HSD1 
LP2-V and LP2-GW male offspring at 21 days of age. Data were obtained from 
immunoblotting experiments. Immu
normalized to β-actin (42 kDa) protein expression. 
unpaired Student’s t-test. Data are represented as arbitrary values. Results are expressed 
as the mean + standard error (SEM). * = Statistically significant from LP2
experimental group. 
protein (34 kDa), and E) SREBP-1 protein (68 kDa) 
noblots were quantified using densitometry and 
Data were analyzed using the 
-
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Figure 3.3: The effect of neonatal GW3965 administration (25mg/kg) on A) body weight 
and B) liver weight in LP2-V, LP2
age. Data are represented in grams (g). 
followed by Tukey’s post-hoc test.
(SEM). * = Statistically significant. n=5
 
 
 
 
 
 
 
 
 
 
-GW, C-V, and C-GW male offspring at 4 m
Data were analyzed using the one-way ANOVA 
 Results are expressed as the mean + standard error 
-9 per experimental group. 
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Figure 3.4: A) Intraperitoneal glucose tolerance tests (2g/kg) administered to fasted male 
offspring at 4 months of age. LP2
together at each time point (t=0, 5, 10, 15, 30, 60, 120 minutes) using the one
ANOVA followed by Tukey’s post
GW, C-V, and C-GW animals. Area under the curve was calculated using 
Prism software and analyzed using the one
test. n=4-8 per experimental group. Results are expressed as the mean 
(SEM). * = Statistically significant (
significant (C-GW versus LP2
 
 
 
 
 
 
 
-V, LP2-GW, C-V, and C-GW animals were analyzed 
-hoc test. B) Area under the curve of LP2
-way ANOVA followed by Tukey’s post
+ standard error 
C-GW versus all groups; p<0.05). + = Statistically 
-V; p<0.05). 
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Figure 3.5: The effect of neonatal GW3965 administration (25mg/kg) on A) fasted 
resting glucose, B) fasted resting insulin, and C) fasted resting triglyceride levels in LP2
V, LP2-GW, C-V, and C-GW male offspring at 4 months of age. Fasted resting glucose 
was obtained prior to the glucose tolerance test. Fasted resting insulin and fasted resting 
triglyceride levels were obtained from the procedures described in the methods section. 
Data are represented as raw values. 
followed by Tukey’s post-hoc test.
as the mean + standard error (SEM). * = Statistically significant (p<0.05).
 
Data were analyzed using the one-way ANOVA 
 n=4-8 per experimental group. Results are expressed 
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Figure 3.6: The effect of neonatal GW3965 administration (25mg/kg) on the 
hepatic levels of A) LXRα protein (50 kDa), B) PEPCK protein (62 kDa), C) G6Pase 
protein (36 kDa), and D) 11β
at 4 months of age. Data were obtained from 
Immunoblots were quantified 
protein expression. Data are represented as arbitrary values.
unpaired Student’s t-test. Results are expressed as the mean 
Statistically significant from C
 
 
-HSD1 (34 kDa) protein in C-V and C-GW male offspring 
western immunoblotting experiments. 
using densitometry and normalized to β-actin (42 kDa) 
 Data were analyzed using an 
+ standard error (SEM). * = 
-V. n=4-8 per experimental group. 
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Figure 3.7: The effect of neonatal GW3965 administration (25mg/kg) on the 
hepatic levels of A) ACC protein (265 kDa), B) FAS protein (273 kDa), C) SREBP
protein (68 kDa), and D) SCD
months of age. Data were obtained from w
Immunoblots were quantified using densitometry and normalized to 
protein expression. Data are represented as arbitrary values. 
unpaired Student’s t-test. Results are expressed as the mean 
Statistically significant from C
 
 
-1 (37 kDa) protein in C-V and C-GW male offspring at 4 
estern immunoblotting experiments. 
β-actin (42 kDa) 
Data were analyzed using an 
+ standard error (SEM). * = 
-V. n=4-8 per experimental group 
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3.4 Discussion 
 
 Our study demonstrates for the first time that administration of the Liver X 
Receptor agonist GW3965 during the rat neonatal period has permanent and profound 
effects on the expression of hepatic gluconeogenic and lipogenic genes in adult life. From 
our results, it appears that activation of LXR activity in neonatal life in non-MPR 
offspring leads to the generation of a phenotype very similar to the metabolic syndrome: 
impaired glucose tolerance, hyperinsulinemia, hypertriglyceridemia, increased 
gluconeogenic gene expression, and increased lipogenic gene expression.  
 Our initial hypothesis and prediction was that administration of GW3965 during 
the neonatal period would rescue the maternal protein restricted animals from developing 
impaired glucose homeostasis. However, this was not the case, as we did not observe 
impaired glucose tolerance in our “LP2” MPR model. Given that the male offspring of 
MPR dams did not exhibit impaired glucose tolerance at our time of measurement (4 
months), we were not able to assess whether or not administration of GW3965 would 
rescue the impaired glucose tolerance phenotype. Although the literature has previously 
found impaired glucose tolerance in the offspring of MPR, studies have also found that 
male rats at 4 months of age do not yet exhibit the impaired glucose tolerance 
phenotype11,42. It is likely the time point that we chose for the study was too early and our 
animals had not yet developed an impaired glucose homeostasis phenotype. For instance, 
Hales and colleagues (1996) found that their MPR rats did not exhibit impaired glucose 
tolerance at 3 months, but developed worsened glucose tolerance at 15 months of age11. 
Chamson-Reig and colleagues (2009) also did not find impaired glucose tolerance in 
male offspring at 130 days of age but they did find signs of insulin resistance42. Females, 
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however, did develop impaired glucose tolerance at 130 days of age42. Recent studies in 
our lab did find impaired glucose tolerance at 130 days of age in MPR male rat offspring, 
however the offspring in that study had the normal protein diet restored earlier 
(immediately after birth in the aforementioned study versus after weaning in this study)20. 
Thus, a variety of factors may have played a role in why our MPR animals did not 
develop impaired glucose homeostasis. 
 Interestingly, there were permanent implications when the control diet animals 
received neonatal administration of GW3965. When the control diet animals received 
GW3965 during the neonatal period (C-GW), they developed impaired glucose tolerance, 
fasted hyperglycemia, as well as patterns of hyperinsulinemia and hypertriglyceridemia. 
In addition, these changes were reflected in the increased protein expression levels of 
various hepatic gluconeogenic genes (G6Pase, PEPCK) and lipogenic (SCD-1) genes. 
Moreover, enhanced protein expression of 11β-HSD1 was found in C-GW animals 
compared to C-V animals, suggesting an increase in the production of glucocorticoids, 
which would then indirectly lead to increased gluconeogenesis.  
 A permanent increase in the expression of G6Pase and PEPCK, two essential 
enzymes in the regulation of hepatic glucose production could very well lead to impaired 
glucose tolerance44,45. Furthermore, the liver is a principle source for insulin clearance46-
48
. Given that the gluconeogenic genes G6Pase and PEPCK are overexpressed in our C-
GW animals and that they display patterns of hyperinsulinemia, hepatic insulin resistance 
may be a major contributor to the impaired glucose phenotype in these animals. To 
further support this, previous studies in liver-specific insulin receptor knockout mice have 
demonstrated hepatic insulin resistance to be a major contributor of impaired hepatic 
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function and glucose intolerance49. Additionally, the study by Michael and colleagues 
(2000) also found severe hyperinsulinemia in their liver-specific insulin receptor 
knockout mice49. Hyperinsulinemia is strongly associated with impaired glucose 
tolerance as well as obesity and hypertension50. In addition, chronic hyperinsulinemia is a 
great risk factor for the development of impaired glucose tolerance, insulin resistance, 
and ultimately diseases such as type 2 diabetes and the metabolic syndrome51. 
 The increased expression of G6Pase and PEPCK may also be attributed to 
increased protein expression of 11β-HSD1. Considering that 11β-HSD1 is responsible for 
the conversion of inactive glucocorticoids to active glucocorticoids, long-term increases 
in this enzyme may lead to chronic elevation of glucocorticoids in the body. 
Glucocorticoids play a major role in the induction of G6Pase and PEPCK52-54, thus the 
elevation of 11β-HSD1 protein expression may play a role in the impaired glucose 
homeostasis and fasted hyperglycemia seen in the C-GW experimental group.  
In addition to impaired glucose homeostasis, neonatal exposure to GW3965 in 
non-MPR male offspring led to the increase in circulating triglycerides. Furthermore, 
there was a significant increase in the protein expression of SCD-1. However, no 
increases in other lipogenic genes were observed. While FAS and ACC are responsible 
for the de novo synthesis of long chain fatty acids, SCD-1 is vital for the production of 
unsaturated fatty acids and ultimately triglycerides in addition to other essential lipids55. 
Elevated SCD-1 activity has been implicated in the development of many chronic 
diseases including diabetes and obesity56-59. In contrast, studies in SCD-1 knockout mice 
demonstrate that these mice exhibit reduced adiposity, increased sensitivity to insulin and 
are resistant to weight gain60. These mice SCD-1 knockout mice also displayed increased 
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expression of genes related to lipid oxidation and a reduction in the expression of 
lipogenic genes60. Furthermore, another study was able to prevent diet-induced obesity 
and improve postprandial glucose and insulin levels in high-fat diet mice through 
administration of antisense oligonucleotide inhibitors of SCD-161. Lastly, studies have 
also demonstrated the involvement of SCD-1 in insulin signaling and carbohydrate intake 
induced adiposity, implicating its possible role in glucose homeostasis62,63. Thus, the 
increase in SCD-1 expression seen in male C-GW offspring is likely to play a factor in 
the possible hypertriglyceridemia and impaired glucose homeostasis seen in these 
animals. 
Of particular interest is that all of the genes that changed in our model are 
transcriptionally regulated by LXR. Yet, LXR expression was unchanged at all time 
points examined. This necessitates a mechanism that allows the temporary neonatal 
administration of GW3965 to continue into adulthood. An ideal candidate for such a 
change would be some sort of epigenetic change such as DNA methylation or a post-
translational modification like histone acetylation/methylation. For instance, in addition 
to the study done by Stoffers and colleagues (2006), where neonatal administration of 
Exendin-4™ prevented the development of diabetes in IUGR rats37, it was subsequently 
discovered by Pinney and colleagues (2011) that this change was effected through an 
epigenetic mechanism64. More specifically, they found that neonatal administration of 
Exendin-4™ permanently restored histone H3 acetylation, decreased histone H3 lysine 9 
dimethylation, and restored histone H3 lysine 4 trimethylation, all signs of chromatin 
opening, on the Pdx-1 promoter in adult IUGR animals64. Furthermore, neonatal 
administration of Exendin-4™ prevented direct DNA methylation around the Pdx-1 
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promoter in adult IUGR rats, another sign of permissive transcriptional status. Thus, it is 
highly probable that the changes mediated by our neonatal administration of GW3965 in 
non-MPR rats (C-GW experimental group) are a result of long lasting epigenetic changes 
that manifest themselves in adulthood. 
Another possible mechanism that may mediate the long-term effects of neonatal 
GW3965 administration is through “endoplasmic reticulum (ER) stress” and the 
subsequent accumulation of misfolded of proteins. Previous studies have implicated the 
role of ER stress and impaired protein synthesis and folding in the development of 
chronic disease65,66. Additionally, ER stress has also been linked to insulin resistance and 
diabetes67-69. More recently, LXR has been linked with both ER stress and insulin 
resistance70. In the study done by Jwa et al. (2012), administration of piperine, an LXR 
antagonist, led to the amelioration of ER stress and improved insulin resistance in mice 
fed a high fat diet70. The authors postulate that the link between LXR, ER stress, and 
insulin resistance may involve the role of LXR in inducing the lipogenic genes and 
subsequent lipid accumulation. Studies from our own laboratory have also implicated 
insulin resistance with attenuated protein synthesis in a similar model of MPR used in 
this study71. However, the role of LXR in relation to these changes was not investigated. 
These findings are significant as there are several cases in which induction of 
LXR may occur during pregnancy. One example is gestational diabetes, which is reported 
to occur in 2-25% of pregnancies in the US and is on the rise72-74. Considering that 
glucose itself has been found to be a direct agonist for LXR31, elevated glucose exposure 
to the fetus during pregnancy may act to induce LXR activation. A common consequence 
of gestational diabetes is that the infants go on to develop impaired glucose tolerance 
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later on in life75. The Pima Indian population exemplifies this phenomenon, where 
approximately 45% of individuals born to gestational diabetic mothers develop type 2 
diabetes76,77. Currently, the mechanism behind why this happens is poorly understood. 
One possible reason for why this occurs is due to an increased glucose load to the fetus 
and development of hyperinsulinemia in the fetus/neonate. As a consequence, many 
infants born to diabetic mothers develop hypoglycemia immediately after birth due to the 
elevated circulating levels of insulin during pregnancy78. Insulin is a potent stimulator of 
LXR and LXR is also an essential mediator of insulin downstream transcriptional 
regulation79,80. Thus, in addition to elevated glucose activation of LXR, prolonged 
hyperinsulinemia during the prenatal and neonatal period also may contribute to 
increased activation of LXR and a phenotype similar to the model used in this study. 
Moreover, gestational diabetes has been found to alter cholesterol transport in the 
placenta, which may affect oxysterol (endogenous LXR activators) concentrations in both 
the mother and the fetus81. Thus, our model of neonatal LXR exposure may very well 
mimic the molecular mechanisms underlying gestational diabetes and how it programs 
the development of impaired glucose tolerance in later life in the offspring. 
In summary, we have produced a phenotype characteristic of the metabolic 
syndrome in non-maternal protein restricted male offspring through neonatal 
administration of the LXR agonist GW3965. Likely through an epigenetic mechanism, 
these changes induced during the neonatal period are permanent and result in a phenotype 
that includes impaired glucose tolerance, fasted hyperglycemia, fasted hyperinsulinemia, 
hypertriglyceridemia, and increased expression of gluconeogenic and lipogenic genes. 
Understanding the role of LXR induction during the neonatal period may help uncover 
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novel roles of LXR and other transcription factors underlying the mechanisms involved 
in the early life programming of chronic disease. For example, exposure to a diet high in 
sugar and cholesterol (natural agonists for LXR) during the neonatal period may pose 
considerable risk for a developing infant, regardless of birth weight and/or growth 
restriction due to the possible induction of LXR and subsequent programmed effects. 
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Discussion 
 
4.1 Summary  
It is now widely recognized that the intrauterine environment may play a role in 
the development of chronic, non-communicable diseases in later adult life. Intrauterine 
growth restriction (IUGR) occurs in many complicated and high-risk pregnancies. The 
evidence strongly suggests that IUGR and the birth of a low birth weight infant increases 
the risk of developing obesity, heart disease, hypertension, and diabetes1-5. The “Barker 
Hypothesis” or “Thrifty Phenotype Hypothesis” postulates that the development of these 
chronic diseases is a result of a programming mechanism that occurs during the 
developmental period6,7. In addition, other complications in pregnancy such as gestational 
diabetes mellitus and maternal obesity may also lead to placental complications and 
increase the risk of developing chronic disease in the offspring8-10. Given the widespread 
prevalence of non-communicable chronic diseases, it is imperative to understand the 
mechanisms underlying how the programming of adult chronic disease occurs during the 
developmental period. Yet, the molecular mechanisms behind how these programming 
changes occur are still largely unknown. While a few mechanisms have been postulated 
(e.g. epigenetic mechanisms, nuclear receptor signaling, oxidative stress, endoplasmic 
reticulum stress, etc.), there is still much to be discovered11.  
Due to its role in glucose12,13, lipid13, and cholesterol homeostasis14, the Liver X 
Receptor (LXR) presents itself as an attractive candidate for mediating some of the 
effects seen in the fetal programming of adult diseases such as type 2 diabetes, 
hypertension, atherosclerosis, and obesity. Overall the present studies provide strong 
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evidence for the involvement of the LXR in the programming of adult chronic disease.  
Based on the work presented in this thesis and others15,16 we strongly believe that LXR is 
implicated in the programming of adult disease, and more specifically, impaired glucose 
tolerance, in our model of maternal protein restriction. We also strongly believe that the 
permanent actions of LXR are both transcriptional and epigenetic in nature.  
In the first study (Chapter 2) we hypothesized that maternal protein restriction and 
the early restoration of protein (at birth) would lead to impaired glucose homeostasis. We 
further hypothesized that the impaired glucose homeostasis would at least be partly 
mediated through alterations in expression of LXR and its downstream target genes 
involved in gluconeogenesis. The study presents evidence for the epigenetic 
downregulation of LXR expression in a model of maternal protein restriction with early 
protein restoration. This repression then leads to altered transcriptional regulation of LXR 
downstream target genes involved directly (G6Pase) and indirectly (11β-HSD1) in the 
induction of gluconeogenesis. The increased hepatic production of glucose then results in 
the observed impaired glucose tolerance observed at postnatal day 130 (Figure 4.1).  
 Given MPR leads to decreases in LXR expression, accompanied by impaired 
glucose tolerance, we sought to investigate whether neonatal intervention with the LXR 
agonist GW3965 would rescue the IUGR phenotype seen in our previous studies15,17. We 
hypothesized that administration of GW3965 during the neonatal period would prevent 
adverse outcomes and prevent the programming of chronic disease in adulthood. The 
study did not support our hypothesis and the results were unanticipated. Surprisingly, 
neonatal administration of GW3965 led to impaired glucose tolerance and fasted 
hyperglycemia in the young adult males of the control diet offspring even though LXR 
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agonists have consistently been demonstrated to have antidiabetic effects18,19. Instead, the 
study presents evidence that neonatal overexposure to an LXR agonist may in fact be 
detrimental, as it appears to induce a metabolic syndrome-like phenotype in adulthood: 
fasted hyperglycemia, impaired glucose homeostasis, fasted hyperinsulinemia, 
hypertriglyceridemia, and increased expression of gluconeogenic and lipogenic genes. 
Many questions in this model remain unanswered. For example, is epigenetic regulation 
occurring at the promoter regions of LXR, G6Pase, and 11β-HSD1, parallel to the low 
protein model (seen in Chapter 2)? Besides LXR, what are other nuclear receptors (e.g. 
GR, ER, PPAR) and signaling pathways (e.g. insulin signaling pathways, cAMP 
signaling pathways) are involved in the programing of the resulting phenotype? Why is 
LXR exhibiting the opposite of its antidiabetic effects when administered in early life 
versus later life (antidiabetic effects)? Investigation of these questions would provide 
much insight on the mechanisms involved in the early life programming of adult disease. 
 Together, these two studies provide strong evidence for the involvement of LXR 
in the programming of adult disease. In both models, MPR and neonatal overexposure to 
an LXR agonist, there is altered LXR expression leading to a long lasting phenotype in 
adulthood. In addition, both models demonstrated similar phenotypes and gene 
expression profiles, suggesting a conserved mechanism with regards to LXR expression 
and activity.  
 
4.2 Limitations and Improvements 
 No study is without its limitations and the present study is no exception. Firstly, 
we decided only to examine males in both of the studies presented. This was to prevent 
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confounding variables associated with either sex, namely differences attributed to female 
estrous cycling, and differing hormone profiles in either sex. Previous studies have also 
demonstrated exacerbated effects of developmental programming in males20. Although it 
was our decision was to investigate only the male-specific effects of our models, by 
neglecting investigation of the females we leave an entire half of the study open to 
question. Other studies have investigated the differences between the sexes and have 
found different mechanisms of programming between males and females20-22. For 
instance, Chamson-Reig and colleagues (2009) found that both males and females display 
altered glucose metabolism, however males were insulin resistant, while females were 
insulin deficient21. Thus, investigation of females would have provided much insight into 
the mechanisms behind fetal programming and how each sex responds to each insult 
differently. 
 Secondly, our evaluation of hepatic gluconeogenesis was limited by the fact that 
we only explored the expression profiles of the genes involved in gluconeogenesis (e.g. 
G6Pase, PEPCK). While this provides a good measure of gluconeogenesis, it does not 
necessarily imply increased activity of these enzymes. We did attempt to do an in vivo 
measure of hepatic gluconeogenic activity through a pyruvate challenge test as described 
by Yao et al. (2006)23 and Meyer zu Schwabedissen et al. (2011)24. However, due to 
limited experience with the technique and the animals not responding well to the 
pyruvate challenge and other complications, we were not confident in the results obtained 
from the experiment. Another option to measure activity would have been to do hepatic 
microsomal extractions and colorimetric measurements of the enzyme products over time 
as previously described25-28. In addition, we speculate that an increase in glucocorticoid 
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synthesis may have contributed to the observed increase in gluconeogenic genes since 
there were increases in 11β-HSD1 and GR expression. However, we did not measure the 
levels of hepatic or circulating glucocorticoids. Unfortunately, this was due to the lack of 
plasma samples at the time of experimentation. Again, measurement of 11β-HSD1 
enzyme activity would also help solidify the present findings. These considerations will 
be taken into account for future cohorts and experiments. 
 Our assessment of insulin resistance may also have been improved. Although we 
did assess protein expression levels for markers of insulin sensitivity in the liver to give 
us a specific evaluation of hepatic insulin resistance, a few other experiments may have 
been done to fully assess insulin resistance. Firstly, a whole body insulin tolerance test 
(or even better, a hyperinsulinemic euglycemic clamp experiment) could be employed, 
although this would not give a direct measure of hepatic insulin utilization. Secondly, 
other markers of insulin resistance could be measured, such as interactions between 
insulin signaling molecules and receptors through protein complex immunoprecipitation 
experiments (Co-IP)29. 
 In the second study (Chapter 3), the main issue was choosing the inappropriate 
maternal protein restriction model with respect to glucose tolerance. We decided on 
restoring the protein in our MPR rats after weaning instead of immediately after birth for 
two reasons. The first reason was based on results obtained previously in our lab by Sohi 
and colleagues15 whereby MPR offspring restored on a control protein diet after the 
weaning period displayed elevated circulating and hepatic cholesterol and altered 
epigenetic regulation of the Cyp7a1 gene in adulthood, implicating that this model was 
consistent in inducing a chronic disease programmed phenotype. Studies by Chamson-
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Reig et al. (2009) have also demonstrated long-term effects in the offspring employing a 
similar model of MPR21. The second reason was based on promising results from our 
initial pilot study, whereby we used the post-weaning protein restoration model and 
found that there was a significant difference between the LP2-V and LP2-GW animals at 
postnatal day 21 in the protein expression of 11β-HSD1 and SREBP-1 (Figure 3.2). 
Although no changes were found in the protein expression of LXR, G6Pase, or PEPCK, 
this still provided encouragement to continue the study because there were significant 
changes in the expression of some LXR-target genes even one week after administration 
of the LXR agonist discontinued. Thus, we continued the study with a second cohort of 
animals taken to postnatal day 130 as presented in Chapter 3. At postnatal day 130, we 
did not observe an impaired glucose tolerance phenotype in the MPR animals. Thus, 
there was no “rescue” or “prevention” of the phenotype. In hindsight, we would have 
chosen the MPR model more similar to the one in Chapter 2, in which the offspring were 
restored on a regular protein diet immediately after birth and displayed consistent 
impaired glucose homeostasis at postnatal day 13017.   
 Finally, considerations must be taken into account with respect to the animals 
themselves. Caution must be taken when interpreting the current data in the context of 
what happens in the human on a physiological and pathophysiological basis. In terms of 
development, it appears that both the rat and human experience similar patterns of 
postnatal development for the liver and pancreas, although the rat does go through a 
higher degree of liver remodeling and maturation during the first 28 days after birth30. 
However, the human liver does not reach full maturation until approximately 5 years after 
birth, suggesting a similar pattern of postnatal development. Another consideration 
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pertinent to the presented studies is that human and rat hepatocytes have been 
demonstrated to respond to the LXR agonist GW3965 quite differently through gene 
expression profile experiments31. For instance, LXR agonists repressed the expression of 
GLUT2, glucokinase (GCK), and pyruvate kinase (PKLR), in human hepatocytes but not 
rat hepatocytes31. Moreover, LXR-mediated transcriptional activation of Cyp7a1 appears 
to only occur in rats but not humans or other mammals32. Thus, it is possible that the 
effects seen in our experiments in neonatal rats may not necessarily mimic the effects 
proposed in humans. Lastly, all experiments were performed in the fasted state. There is a 
significant difference in metabolic gene expression profiles in the fasted and non-fasted 
state33. Considering how important nutritional status is in the regulation of hepatic 
gluconeogenesis and lipogenesis34,35 it is important to take into account the nutritional 
status of the animal in the assessment of its metabolic status. Although the fasted state 
allows us to examine the metabolic profiles of the animals without confounding variables 
(e.g. variable food and water intake), we are curious to see what differences may occur in 
the non-fasted state. 
 
4.3 A New Hypothesis 
 Although we found strong evidence to support our hypothesis in the first study 
(Chapter 2), the hypothesis in the second study (Chapter 3) must be reconsidered. Given 
that neonatal administration did not lead to the rescue of an impaired glucose tolerance 
phenotype, a new hypothesis must be proposed to address the current findings and/or a 
new experiment must be conducted to re-examine the hypothesis. In the case of the latter, 
we would redesign the study such that we use a maternal protein restriction model that 
148 
 
consistently produces a glucose intolerance phenotype. If we were to redesign the study 
to examine the possibility of a phenotype rescue, it would likely be the MPR model used 
in our Chapter 2 study whereby the MPR offspring were restored protein in their diet at 
an earlier time point (immediately after birth). However, we can examine a modified 
hypothesis because we did find an altered phenotype in the control diet animals given the 
LXR agonist. This suggested hypothesis, which aims to cover both Chapters 2 and 3, 
would be as follows: We hypothesize that alterations in LXR expression during the 
neonatal period through various intrauterine insults leads to the long-term 
programming of impaired glucose homeostasis and ultimately the development of 
diseases such as type 2 diabetes and the metabolic syndrome. 
  
 
 
 
 
 
 
 
 
 
 
  
Figure 4.1: A Working Hypothesis for
Glucose Tolerance in a Model of Maternal Protein Restriction
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4.4 Future Directions 
 Though we have begun to characterize the role of LXR in mediating the 
programming effects of adult disease, the issue remains quite complex and there is still 
much to be investigated. As previously mentioned, our model neglects the question of 
what happens in the female offspring of MPR animals and females administered 
GW3965 during the neonatal period. Although we do have preliminary evidence that the 
females do experience impaired glucose tolerance, it is to a much lesser degree than the 
males. This is supported by other studies, whereby males are more susceptible to the 
effects of fetal programming and display exacerbated phenotypes compared to females20. 
The mechanisms underlying these sexually dimorphic observations are still in question. 
Furthermore, it would be worthwhile to investigate more time points in the study for 
several reasons. Firstly, investigation of early time points may reveal critical time points 
at which the programming is occurring. A longitudinal study similar to the one employed 
in the Chamson-Reig et al. study (2009) would reveal when specific changes in 
metabolism occur. For instance by examining both the postnatal day 85 time point and 
the postnatal day 130 time point, Chamson-Reig and colleagues (2009) were able to find 
that impaired glucose tolerance did not occur until at least early adulthood (postnatal day 
130)21.   
 In contrast, it would be of great interest to investigate the current models at later 
time points. Our current time point for sacrifice occurs at postnatal day 130, which is still 
a young age for the rat. The development of many chronic diseases occurs later on in life, 
once the effects of aging are compounded with early life insults. For instance, in the 
Hales et al. study (1996), the effects of MPR in the offspring were not observed at 3 
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months of age, however they occurred at 15 months of age36. It is quite possible that the 
animals in our model have not had the chance to develop other pathologies such as 
obesity, hypertension, atherosclerosis, and heart disease. Future studies may include the 
6, 12, and 15-month time point to observe the progression of the metabolic syndrome and 
cardiovascular disease. A longitudinal study might also be possible, given the proper 
funding and resources. Of interest is also the fact that MPR animals have demonstrated 
decreased longevity, especially in models of accelerated catch-up growth36-38. Although 
some mechanisms have been postulated (e.g. oxidative stress, altered insulin signaling, 
impaired mitochondrial function)39-42, it is still unclear whether the decreased lifespan is a 
result of the development of chronic disease or if the decreased lifespan is itself 
programmed in early life.  
Another area of relevance is the possibility of examining a “double hit” model. In 
this model, an insult during pregnancy is utilized to induce IUGR (insults may include 
maternal protein restriction, total maternal nutrient restriction, uterine artery ligation and 
hypoxia) and then a second insult is compounded to the intrauterine insult in postnatal 
life. A common postnatal insult is through the feeding of a high fat or “western diet” that 
usually generates an obese phenotype43. Double hit models are of great interest because 
they are especially relevant in today’s society given the increasing prevalence of the 
consumption of high sugar and high fat “western diets”. This is especially important as 
the population begins to develop chronic diseases at a younger age due to poor lifestyle 
choices in diet and lack of exercise44,45. 
The second study (Chapter 3) is still largely incomplete, and additional 
experiments are required to expand on the current findings. Firstly, quantitative real-time 
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PCR experiments are required to investigate whether steady-state levels of mRNA are 
increased in our genes of interest (LXR, G6Pase, PEPCK, 11β-HSD1, SCD-1, ACC, 
FAS, SREBP-1). Although the long-term expression of LXR was not altered by neonatal 
GW3965 treatment, it is still conceivable that LXR activity itself is enhanced long-term. 
Thus, chromatin immunoprecipitation should be employed to investigate this possibility 
by measuring the binding of LXR to its target promoters. In addition, post-translational 
and epigenetic mechanisms need to be further explored to help explain the long lasting 
effects of neonatal LXR agonist treatment. For example, administration of the LXR 
agonist T0901317 in chick embryo hepatocytes has been demonstrated to increase 
activity of the LXR/RXR heterodimer in addition to increasing the acetylation of histone 
H3, lysine 4 around the LXRE of the ACC gene promoter (a downstream target of LXR 
activation)46. Hence, the agonists themselves may be responsible for mediating epigenetic 
changes. Histone modifications are likely key mechanisms that may be involved in the 
altered expression of our genes of interest. Investigation of acetylated histone H3 lysine 
9, trimethylated histone H3 lysine 27, trimethylated histone H3 lysine 4, and binding of 
RNA polymerase at the promoters of our genes of interest may provide a better 
understanding of the transcriptional regulation occurring at these gene promoters. 
Furthermore, the examination of direct DNA methylation through bisulfite sequencing 
experiments may provide further clues on epigenetic regulation.  
 
4.5 Conclusion 
It is clear from the results of the present study that the Liver X Receptor is 
emerging as a key factor in mediating the early life programming of adult chronic 
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diseases. In both studies, we found that alterations in LXR expression or activation either 
short-term during the neonatal period or long-term in adulthood led to detrimental effects 
in adulthood. Whether these changes are due to LXR directly or due to cross talk with 
other nuclear receptors and transcription factors is presently unknown. However, it is 
clear that LXR is involved and it is directly influencing the transcription of various genes 
involved in hepatic gluconeogenesis. From both studies, these genes appear to be critical 
points of regulation, whereby aberration in expression can lead to phenotype changes: 
G6Pase, PEPCK, 11β-HSD1, SCD-1 and possibly GR. 
Studies from other groups as well as from colleagues in our lab and have also 
demonstrated the involvement of LXR in the programming of adult disease. Sohi et al. 
(2011)15 have previously demonstrated elevated LXR expression concomitant with 
increased LXR binding to the Cyp7a1 gene in young MPR rats, while Ma et al. (2013, 
unpublished data) has demonstrated elevated LXR expression in adult male offspring of 
pregnant rats exposed to moderate doses of nicotine (as seen in moderate smokers). 
Moreover, van Straten and colleagues (2012) have demonstrated altered levels of LXR in 
embryonic day 19.5 MPR offspring as well47. These studies further cement the role of 
LXR in the programming of adult disease. 
While we provide evidence for the involvement of LXR in the programming of 
chronic disease in IUGR animals, there are many other transcription factors and 
mechanisms that may contribute to the programming of adult disease. These transcription 
factors include other nuclear receptors such as the peroxisome proliferator-activated 
receptors (PPAR), glucocorticoid receptor (GR), and estrogen receptor (ER)17. In 
addition, other mechanisms of action may include elevated oxidative stress and 
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endoplasmic reticulum stress and altered epigenetic profiles17. It should be noted that it is 
likely a combination of all of these factors and mechanisms that contribute to the 
programming of adult disease. Similarly, there is a high likelihood of cross talk between 
LXR and the other nuclear receptors, transcription factors, and co-activators/co-
repressors. For instance, studies have demonstrated possible cross talk between LXR and 
GR based on the existence of putative GR binding sites on the LXR promoter48. 
Furthermore, GR may require LXR to induce its effects and LXR induction has been 
demonstrated to suppress GR-mediated actions49,50. Thus, the mediators of the 
developmental programming of adult disease are extremely complex and multifactorial in 
nature. 
Finally, and most importantly, once we discover these mechanisms and collect the 
data, what becomes the next task? The pivotal task ahead is learning how to translate 
these data and prevent the development of these chronic diseases, which are now 
devastating health care systems around the world.  Intervention at early and critical time 
points in development to prevent adverse outcomes is key. As research continues, more 
interventional approaches are being employed in animal models. A few examples 
include: administration of key transcription factor and nuclear receptor agonists (such as 
Exendin-4™)51, administration of antioxidants such as tempol, resveratrol, vitamin C 
(ascorbic acid)52-54, and folic acid supplementation55,56. Clearly, there are many avenues 
to take for the intervention of programmed adult diseases, further adding to the 
complexity of how these mechanisms work and how they can be reversed57. It is 
imperative that we come to understand not only the molecular mechanisms behind the 
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fetal programming of chronic adult diseases but also how we can use this understanding 
to prevent further development of these diseases.  
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